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 The rise in obesity and its association with insulin resistance is attributed to 
excess caloric consumption and sedentary living. Skeletal muscle has been demonstrated 
to be the primary tissue driving insulin resistance before beta-cell failure in type 2 
diabetes, therefore it is a target for anti-diabetic drugs. The mechanisms leading to the 
development of skeletal muscle insulin resistance in obesity and type 2 diabetes remains 
unresolved, but defects in skeletal muscle fatty acid oxidation have been implicated in the 
etiology. Malonyl-CoA decarboxylase (MCD) has been a target of investigation because 
it regulates the concentration of malonyl-CoA, a central metabolite in fatty acid 
biochemistry. The purpose of this thesis was to determine the in vivo role of MCD in 
skeletal muscle of obese and insulin resistant mouse models. We generated mice 
expressing a muscle specific transgene for MCD (Tg fMCD
Skel
) regulated 
posttranslationally by the small molecule, Shield-1.  Tg fMCD
Skel
 and control mice were 
placed on either a high fat or low fat diet for 3.5 months. Obese and glucose intolerant as 
well as lean control Tg fMCD
Skel
 and nontransgenic control mice were treated with 
Shield-1 and changes in their body weight and insulin sensitivity upon induction of MCD 
were determined. Obese Tg fMCD
Skel 
mice had no improvement in body weight or 
glycemic control after 2 weeks of MCD induction.  Obese Tg fMCD
Skel 
and control mice 
were then subjected to an acute Shield-1 treatment prior to an in vivo insulin stimulation. 
Compared to obese nontransgenic controls, Tg fMCD
Skel
 mice had decreased AKT 
signaling in the skeletal muscle. In addition, oxidative metabolism genes were down-
regulated at the transcriptional and protein level compared to obese controls. The 
suppression of mitochondrial oxidative genes suggests an unexpected redundant and 
 iii 
metabolite driven regulation of gene expression through the transcriptional regulator, 
PPARα.  Together, these data indicate that induction of MCD leads to decreased fatty 
acid oxidation gene expression, impairs skeletal muscle insulin sensitivity, and implicates 
PPARα in a fatty acid induced down regulation of oxidative genes in vivo to regulate the 
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 Excessive adiposity is a major health problem in the United States where > 60% 
of adults are overweight and greater than one-third are clinically obese as defined as a 
Body Mass Index of >30. Obesity is a major risk factor for insulin resistance, Type 2 
Diabetes, cardiovascular and cerebrovascular disease, hypertension, stroke, and other 
chronic disorders that lead to morbidity and mortality (1-3).  Beyond the accumulation of 
fat in adipose tissue, hyperlipidemia in obese and diabetic patients is a major contributing 
factor for stroke and heart attack. The magnitude of obesity related vascular disease is 
staggering. Obesity related disease is predicted to become the leading cause of 
preventable death over the next decade. Lifestyle interventions used to promote weight 
loss are met with high rates of recidivism (4). Individuals regain one third of their lost 
weight in the first year after treatment and in some cases continue weight gain in their life 
time. Researchers and clinicians struggle to find useful strategies for successful weight 
loss maintenance, thus adding emphasis to the development of novel approaches to 
weight loss therapy. 
 Obesity is the result of energy imbalance. Thus, when caloric intake exceeds 
expenditure, metabolic flux is directed into energy reserves, primarily triglyceride in 
adipose tissue. Conversely, when caloric expenditure exceeds intake, these reserves are 
mobilized to provide physiological fuel for peripheral tissues. To alter body weight, in 
particular adiposity, either energy intake and/or expenditure must be altered. The brain 
and peripheral tissues play an important role in regulating the homeostatic mechanisms  
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that control energy balance and therefore, the magnitude of body fat reserves (5-9). The 
crosstalk mediated through multiple organ systems work to regulate complex metabolic 
processes by coordinating their actions through secreted hormones (e.g., insulin, 
glucagon, leptin, adiponectin, FGF21) to maintain the integrated control of whole-body 
metabolism (Figure 1). Disruption of these hormone-mediated metabolic circuits 
frequently results in disrupted energy metabolism and related pathologies.  
 
             
Figure 1-1: Integrated control of Metabolism. Signals such as leptin and insulin are 
secreted in proportion to the size of the fat mass and circulate in the blood. They enter the 
brain and act at the level of the hypothalamus. Neuroendocrine signals from the stomach, 
the gastrointestinal system and the liver are sent to the hindbrain, providing information 
about the food that is eaten:its taste and chemical content, and how much the stomach is 






Obesity Induced Insulin Resistance and Type -2-Diabetes  
 Impaired activity of the insulin signaling pathway, eventually resulting in insulin 
resistance can be caused by genetic and/or acquired through poor lifestyle and 
environmental factors (10, 11). The obesity epidemic is linked with the rise of inulin 
resistance and type 2 diabetes throughout in the United States (Figure 2), most 
commonly acquired through a sedentary lifestyle, increased food consumption and aging  
(10-12). While genetic causes or predispositions toward insulin resistance within 
populations have been suggested, they are poorly understood (13). Environmental factors, 
such as excessive adiposity and sedentary lifestyles, mentioned above are contributing 
factors for the rise in obesity related insulin resistance (14). The mechanisms of insulin 
resistance are not clear, but are linked to mitochondrial deficiency 
  
 
Figure 1-2. Maps of Diagnosed Diabetes and Obesity in 1994, 2000, and 
2010 (2011). Source:  CDC’s Division of Diabetes Translations. National 
Diabetes Surveillance System. Source: http://www/cdc.gov/diabetes/statistics. 
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inflammation, ER stress, lipid storage in non-adipose tissues, and cancer (12, 15, 16). 
Insulin resistance is defined as the failure of insulin sensitive target tissues to respond to 
the effects of circulating insulin.  Impaired insulin sensitivity occurs in the skeletal 
muscle, liver and adipose tissue. (17).  
 Although they share similar mechanisms in development, insulin resistance and 
type-2-diabetes are different. Type 2 diabetes involves pancreatic β-cell failure due to the 
overwhelming demand for insulin. Increased insulin synthesis and secretion from β-cells 
leads to an expansion of the β-cell mass until β-cells can no longer compensate for 
decreased tissue insulin sensitivity. The mechanisms involved in the transition from an 
insulin resistant state to overt diabetes remains unclear. Type 2 diabetes is projected to 
afflict 366 million people worldwide by 2020 based on 2004 estimates (14). Updated 
figures collected by the International Diabetes Federation show this estimate has been 
surpassed in 2012 (Figure 3). The best preventative therapy is to decrease body weight 
and increase healthy lifestyle habits; however, the general public approaches lifestyle 
interventions through diet and exercise with resistance and failure. Typical, lifestyle 
interventions have high recidivism rates, with patients regaining one third of their weight 
after the first year and, at times continuing (4).  Pharmacological interventions (e.g. 
orlistat and sibutramine) are often of limited effectiveness at promoting substantial 
weight loss (5-10%) (4).  As the rates of obesity and insulin resistance continue to 
increase, understanding the mechanisms involved in the development of these and other 





Insulin and Glucagon 
 Hormones are important for regulating biochemical switches in tissues in 
response to changing nutritional states. Glucose homeostasis in maintained by the 
pancreatic hormones: insulin and glucagon.  They work in a reciprocal manner to affect 
circulating blood glucose concentration. Insulin is secreted in response to elevating high 
blood sugar, obtained after eating a meal. Insulin reduces blood glucose by promoting 
glucose uptake by the muscle, red blood cells, liver, and adipose. Glycogen, a polymer of 
glucose, is synthesized in the liver and muscle during the fed response and is the short -
term energy storage derived from sugars. The liver and adipose tissue shuttle glucose 
towards the production of fatty acid biosynthesis, promoting fat storage.  In the fasted 
state ([high glucagon: low insulin]), glucagon is secreted by the pancreatic alpha cells to 
Figure 1-3. International Diabetes Atlas, 5
th
 Edition, 2012 Update.  The Latest 
Global and Regional Diabetes Statistics. Source: International Diabetes Federation 
http://www.idf.org/diabetesatlas 
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increase blood glucose levels by stimulating the conversion of glycogen to glucose in the 
liver and muscle, while breaking down fat and protein into glucose, which is secreted into 
the blood to maintain blood glucose levels.     
 
Insulin Signaling  
 Insulin regulates efficient energy storage by partitioning dietary substrates 
towards anabolic metabolism in order to make energy available for use when insulin 
levels are low. Following the ingestion of a meal, insulin is released from the pancreatic 
islet β-cells and activates its receptor on fat, muscle, and liver cells to increase glucose, 
fatty acid, amino acid uptake and stored while simultaneously blocking the breakdown of 
these stored energy reserves. Insulin action is mediated through the activation of the 
insulin signaling pathways (Figure 4) (18). Insulin binds to the insulin receptor (IR), 
which leads to the autophosphorylation of the IR and causes the recruitment and 
phoshphorylation of multiple scaffolding proteins, including the insulin receptor substrate 
(IRS) proteins, Src-homology-2containing protein (SHC), and the c-Cbl  (CBl) 
protooncogene. Phosphorylation of the IRS proteins, such as IRS1 and IRS2, leads to the 
recruitment of the p85 regulatory domain of phosphatidylinositol 3-kinase (PI3K) and its 
association with the p110 catalytic domain of PI3K (18). Activated PI3K converts 
phosphatidylinositol-4,5-bisphosphate (PIP2) to phosphatidylinositol-3,4,5-triphospahte 
(PIP3). PIP3 elicits additional signaling by providing binding sites to the pleckstrin 
homology (PH) domains of downstream kinases, such as phosphoinositide-dependent 
protein kinase-1 (PDK-1), PDK-2, and protein kinase B (Akt). Activation of the Akt 
kinase leads to the phosphorylation of downstream targets, such as glycogen synthase 
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kinase -3 (GSK-3) and AS160 Rab GTPase activating protein (GAP) (19). AS160 
interacts with small GTPase RAB10 to translocate glucose transporter-4 (GLUT-4) 
containing vesicles to the cell surface. The culmination of this insulin signaling cascade 





Figure 1-4. Critical Nodes of Insulin Signaling.  Critical nodes form an important 
part of the signaling network that functions downstream of the insulin receptor 
(IR) (black arrows) and the insulin growth factor-1 receptor (IGF1R) (blue 
arrows). Signalling pathways that are activated by cytokines such as tumour necrosis 
factor-  (TNF ), interleukin-6 (IL-6), and leptin interfere with insulin signalling 
through crosstalk (orange and red arrows). Three important nodes in the insulin pathway 
are the IR, the IR substrates (IRS) 1–4 (light blue box), the phosphatidylinositol 3-
kinase (PI3K) with its several regulatory and catalytic subunits (light green box), and the 
three AKT/protein kinase B (PKB) isoforms (pink box). Downstream or intermediate 
effectors, as well as modulators, of these critical nodes include atypical protein kinase C 
(aPKC), Akt substrate of 160 kDa (AS160), Cas-Br-M (murine) ecotropic retroviral 
transforming sequence homologue (Cbl), Cbl-associated protein (CAP), cell-division 
cycle 42 (CDC42), extracellular signal-regulated kinase 1 and 2 (ERK1 and ERK2), 
forkhead box O1 (FOXO1), glycogen synthase kinase 3 (GSK3), Janus kinase (JAK), c-
Jun-N-terminal kinase (JNK), mammalian target of rapamycin (mTOR), p90 ribosomal 
protein S6 kinase (p90RSK), phosphoinositide-dependent kinase 1 and 2 (PDK1 and 2), 
phosphatase and tensin homologue (PTEN), protein tyrosine phosphatase-1B (PTP1B), 
Ras, Rac, Src-homology-2-containing protein (Shc), suppressor of cytokine signalling 
(SOCS), signal transducer and activator of transcription (STAT), and Ras homologue 
gene family, member Q (ARHQ; also called TC10). Dashed arrows represent an 
activation process with less intensity. Nature Reviews Molecular Cell Biology 7, 85-96 
(February 2006). 
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Metabolism of substrates for energy usage: β-Oxidation 
 Degradation of fatty acids by Beta-oxidation is a multi strep process that occurs in 
most tissues, including the liver, cardiac muscle, pancreas, skeletal muscle, and brown 
adipose tissue at different rates. It is the process by which organisms utilizes excess 
energy from fatty acids and triglycerides. Oxidation rates change in response to a variety 
of stimuli including fasting, re-feeding, exercise, and disease (20-24) The oxidation of 
long-chain fatty acyl-CoA begins with the transport of the fatty acid across the 
mitochondrial membrane by the aid of the carnitine shuttle enzymes: CPT1, CACT, and 
CPT2  (Figure 5).  Next, oxidation of long chain fatty acids proceeds by 4 enzymatic 
steps in the mitochondrial matrix (Figure 5).  In the first step, acyl-CoA dehydrogenase 
dehydrogenates the long chain fatty acyl-CoA. In the second step, trans-Δ
2
enoyl-coA 
hydratase hydrates the intermediate at the double bond to form L-3-hydroxyl-CoA. In the 
third step, hydroxyl-acyl-CoA dehydrogenase oxidizes L-3-hydroxyl-CoA to form 3-
ketoacyl-CoA. In the last step, 3-ketoacyl-CoA thiolase cleaves 3-ketoacyl-CoA to form 
acetyl-CoA and a fatty acyl-CoA that was shortened by two carbons and an acetyl-CoA.  
In summary, each round of oxidation produces acetyl-CoA and a shortened 2-carbon fatty 
acyl-CoA product that re-enters the 4-step cycle until the fatty acyl-CoA species is 
completely oxidized into acetyl-CoA. Acetyl-CoA enters the TCA cycle for further 
conversion and produces CO2.  The number of acetyl-CoA produced depends on the 
carbon length of the fatty acid being oxidized. This process produces NADH and 
FADH2. One FADH2 is produced in step 1 and NADH in the third step.  NADH and 




Figure 1-5. Overview of Fatty Acid Oxidation. Fatty acids primarily enter a 
cell via the fatty acid protein transporters, FATP and CD36 on the cell surface. 
Once inside the cytoplasm, acyl-CoA synthetase (ACS) adds a CoA group to 
the fatty acid. The fatty acyl-CoA enters the carnitine shuttle system where 
CPT1 converts the fatty acyl-CoA to a fatty-acyl-carnitine. The fatty acyl-
carnitine is transported by the carnitine acyl-carnitine translocase (CACT) 
across the inner mitochondrial membrane to the mitochondrial matrix. Next, 
CPT2 converts the fatty acyl-carnitine back to fatty acyl-CoA. The fatty acyl-
CoA enters the fatty acid β-oxidation pathway, resulting in the production of 
one acetyl-CoA from each round of β-oxidation. This acetyl-CoA then enters 
the TCA cycle. The NADH and FADH2 produced by both β-oxidation and the 
TCA cycle are used by the electron transport chain to produce ATP.  
http://lipidlibrary.aocs.org/animbio/fa-oxid/index.htm 
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Metabolism of substrates for energy storage: De novo fatty acid synthesis 
 The pathway for de novo fatty acid synthesis uses a different set of enzymes from  
β-oxidation pathways. De novo fatty acid synthesis occurs in the cytoplasm of multiple 
tissues such as the liver, adipose, brain, and mammary glands. However, the input to fatty 
acid synthesis begins with cytoplasmic acetyl-CoA, derived mainly from the glycolytic 
breakdown of glucose. The end product of glycolysis, pyruvate enters the mitochondria 
and into the TCA cycle where pyruvate dehydrogenase decarboxylates pyruvate to form 
acetyl-CoA. Next, acetyl-CoA Carboxylase (ACC) catalyzes the biotin-dependent 
carboxylation of acetyl-CoA to malonyl-CoA in the highly regulated and committed step 
of fatty acid biosynthesis.  ACC is positively regulated by the tricarboxylic acid (TCA) 
intermediate, citrate, which is also the carbon source for cytoplasmic acetyl-CoA after 
cleavage by ATP:citrtate lyase.  The product of ACC, malonyl-CoA is used by fatty acid 
synthase (FAS) as the chain elongation unit for the reiterative reductive biosynsthesis of 
long chain fatty acids. Seven molecules of malonyl-CoA and one molecule of acetyl-CoA 
interact with FAS in a multi step process to produce the 16 carbon chain length fatty acid, 
palmitate. 
 
Malonyl-CoA: A Dynamic Metabolic Signaling Molecule  
 The mechanisms by which obesity leads to insulin resistance and type-2-diabetes 
have been difficult to parse into one unifying theory. It is clear that insulin resistance is 
the physiological response of cells to a state of over-nutrition and insulin action. Insulin 
sensitive, target tissues, such as the liver, can sense changes in nutrition status, termed 
“nutrient sensing”, through a complex network of highly regulated metabolic pathways. 
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Accordingly, glucose and fatty acids function as the two primary indicators of energy 
surplus, by serving as substrates for energy sensing pathways.  The relationship between 
lipid and glucose metabolism is intimately connected through coordinated regulation of a 
small three-carbon metabolite, malonyl-CoA. 
 Originally identified by Salih Wakil in the late 1950s, malonyl-CoA is produced 
by the carboxylation of acetyl-CoA by the enzyme, acetyl-CoA carboxylase (ACC) 
(Figure 6). The reaction requires ATP, biotin, and bicarbonate and occurs in the 
cytoplasm of mammalian cells (Figure 7). It serves as an intermediate substrate in fatty 
acid metabolism by serving as the chain elongation unit for fatty acid synthetase (FAS) 
for the production of long chain fatty acids. Malonyl-CoA also functions as the allosteric 
inhibitor of carnitine palmitoyltransferase-1 (CPT1), the rate-limiting enzyme in fatty 








Figure 1-6.  Synthesis of Malonyl-CoA.  The key regulating enzyme of lipogenesis is 
acetyl-CoA carboxylase, which catalyzes the synthesis of malonyl-CoA from acetyl-
CoA and CO2. Modified from source: Biochemistry, Seventh Edition. 2012. W. H. 







 Malonyl-CoA is also formed within the mitochondria and peroxisomes and their 
physiological significance within these organelles is starting to become clear. Recently, 
data has emerged to demonstrate malonyl-CoA is actively produced within the 
mitochondrial matrix. ACSF3 is a mitochondrial malonyl-CoA synthetase enzyme that 
converts both methylmalonate and malonate into methylmalonyl-CoA and malonyl-CoA, 
respectively (25). Individuals with mutations in ACSF3 have elevated levels of malonic 
Figure 1-7.  Summary of malonyl-CoA metabolism and its compartmentation in 
mammalian cells. Also shown is carnitine palmitoyltransferase 1 (CPT1), with an 
indication of its topology in the mitochondrial outer membrane and its inhibition by 
malonyl-CoA. ACC, acetyl-CoA carboxylase; FAS, fatty acid synthase; MCD, malonyl-
CoA decarboxylase; PCC, propionyl-CoA carboxylase.  Saggerson D. 2008, Annu. Rev. 
Nutr. 28:253-72 
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and methylmalonic acid in the urine and malonylcarnitine in the plasma, which is thought 
to cause a range of neurological disorders (26, 27). Although the origin of malonate 
metabolism in humans is not known, it is a competitive inhibitor of succinate 
dehydrogenase or Complex II of the electron transport chain (28). Therefore, the function 
of ACSF3 to is to prevent methylmalonic and malonic acid from accumulating by 
diverting it to the production of malonyl-CoA. It has been speculated that mitochondrial 
malonyl-CoA can be used for the production of lipoic acid and the production of long 
chain fatty acids by the mitochondrial FAS (FAS type II enzyme) (29). However, it 
remains unknown how changes in mitochondrial malonyl-CoA can affect rates of fatty 
acid oxidation and synthesis. 
 
ACC and MCD Regulate Malonyl-CoA Concentration 
 Two opposing enzymes, ACC and MCD, regulate malonyl-CoA concentration in 
multiple tissues and organelles. ACC is present as two isoforms, ACC1 and ACC2. 
ACC1 is localized in the cytoplasm and is the predominantly isoform expressed in 
lipogenic tissues, such as the liver and adipose tissue. ACC1 is thought to function as the 
provider of cytoplasmic malonyl-CoA for lipogenesis (30, 31). ACC2, positioned on the 
mitochondrial outer membrane, is found predominately in oxidative tissues, such as the 
skeletal muscle and heart (32, 33). This isoform is thought to function as the producer of 
malonyl-CoA near the mitochondrial surface to directly inhibit CPT1 activity and prevent 
fatty acids from entering oxidative metabolism. Both isoforms are expressed at varying 
levels in lipogenic and oxidative tissues and they are primarily regulated through 
allosteric inhibition and protein phosphorylation events. Inactivation of ACC by 
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phosphorylation is regulated by protein kinase A (PKA) and AMP-activated protein 
kinase (AMPK) (34, 35). AMPK activation favors fatty acid oxidation by decreasing 
malonyl-CoA concentration as a result of phosphorylating and inhibiting ACC. 
 Malonyl-CoA concentration is also dictated by the activity of Malonyl-CoA 
decarboxylase (MCD), an enzyme whose role is to convert malonyl-CoA to acetyl-CoA 
and CO2. Human MCD is encoded by a single gene and produces three isoforms localized 
to the cytoplasm, mitochondria, and peroxisomes (36). Humans with mutations in the 
MCD gene display elevated urinary malonic acid, stunted growth, cardiomyopathy, and 
mental retardation; similar conditions to those seen in individuals with mutation in 
ACSF3 as described above (37-40). Gene expression studies of human MCD mRNA 
analysis show skeletal muscle and heart expressing the highest levels of MCD, while the 
kidney, brain, lung, pancreas contain appreciable levels of activity (36). Its activity and 
expression has been demonstrated to play a key role in promoting fatty acid oxidation, 
while pharmacalogical inhibition of the MCD enzyme has been implicated in playing a 
cardio protective role in ischemia and reperfusion recovery, and displaying toxicity 
towards human breast cancer cells (41, 42).  
 
Malonyl-CoA Targets CPT1  
 The role of the mitochondrial carnitine palmitoyltransferase 1 (CPT1) protein is to 
catalyze the exchange of CoA on a long chain fatty acyl CoA for carnitine. This exchange 
allows the long chain fatty acyl species to traverse the mitochondrial membranes, with 
the aid of an additional enzyme, carnitine palmitoyltransferase II (CPT2) and transporter, 
carnitine-acylcarnitine translocase (CACT), where it can undergo oxidation in the 
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mitochondrial matrix. In mammalian cells, CPT1 exists as three isoforms that are 
encoded by three different genes: CPT1A, CPT1B, and CPT1C (43). The liver expresses 
CPT1A, while the CPT1B isoform is predominately expressed in the heart and skeletal 
muscle, and brown adipose tissue. The brain expresses all three isoforms, but CPT1C is 
exclusive to the brain.  CPT1C is atypical from the other CPTs because it is located in the 
ER and does not catalyze the same reaction as CPT1A and CPT1B (44). Metabolomics 
studies have suggested a role for CPT1C in oxidative stress based on an increase in 
oxidized glutathione; however, it’s precise role remains unclear (45). 
 CPT1’s other physiological role is being a target for malonyl-CoA inhibition 
during the fed state to prevent the oxidation of long chain fatty acids in the mitochondria 
(46). The interaction between malonyl-CoA and CPT1 exists in the liver, cardiac and 
skeletal muscle, brain, and pancreatic β-cells. Even though CPT1A and CPT1B share 
62% amino acid identity, the CPT1 isoforms present varying sensitivities toward 
malonyl-CoA inhibition.  CPT1A has a lower affinity for malonyl-CoA than CPT1B, 
making oxidation more finely tuned in the muscle than in the liver. Works by several labs 
have demonstrated CPT1A sensitivity is modulated by interaction between its NH2 and 
COOH termini and its modulation depends on various physiological states (47). 
 
Metabolic Fuel Switching  
 Mechanisms have evolved to control the cross talk between pathways of glucose 
utilization and fatty acid oxidation. The glucose-fatty acid cycle, introduced by Sir Phillip 
Randle, adds an additional level of control to metabolic fuel switching within tissues on 
top of the established hormonal regulation by insulin and glucagon (48-50). The cycle 
 18 
describes the interactions between substrates, in particular, the inhibition of glucose 
oxidation by fatty acids or ketones without hormonal intervention. During the fasted 
state, lipolysis is triggered to catabolize stored triacylglycerol (TAG) into glycerol and 
free fatty acids. Lipoylsis allows free fatty acids to be released into circulation for use by 
peripheral tissues to meet their energy needs. Oxidation of fatty acids and production of 
ketone bodies fulfill the local energy needs in the liver while other tissues oxidize ketone 
bodies. This mechanism allows fatty acids and ketones to spare glucose for the brain 
during starvation. Inhibition of glucose oxidation occurs at the level of inhibition of 
hexokinase, phosphofructokinase, and pyruvate dehydrogenase by products generated 
from the β-oxidation pathway (Figure 8). Randle originally described the mechanism to 
work in the heart and diaphragm (48). Additional studies have shown the mechanism 
occurs in the liver, pancreatic β-cells, skeletal muscle and adipose tissue. The glucose 
fatty acid cycle takes affect in the fed state after a high fat meal or after exercise. Under 
these circumstances, the non-oxidized glucose is spared and routed toward glycogen 
production.  
 In the late 1970’s, Dennis McGarry and his colleges demonstrated that high 
glucose concentrations inhibit fatty acid oxidation through malonyl-CoA mediated 
inhibition of carnitine palmitoyltransferase-1 (CPT1), the rate-limiting step in fatty acid 
oxidation. This reciprocal mechanism has been termed the “reverse glucose fatty acid 
cycle.” Changes in malonyl-CoA concentration allow the liver to transition between fed 
and fasted states. These changes are also regulated by the hormonal stimulation of insulin 
and glucagon. In the fed state, [low glucagon : high insulin] signals the liver towards fatty 
acid synthesis by converting glucose to fatty acids and then to formation of long chain 
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acyl-CoAs. During the fed state, the pool of malonyl-CoA, produced from the ACC 
reaction, increases and inhibits CPT1, ensuring that the newly formed long chain acyl-
CoAs react with glycerol phosphate to form triacgylcerides that are then exported from 
the liver in the form of VLDL (Figure 9). Conversely, following the shift in the [high 
glucagon:low insulin] in the fasting or diabetic state, the fatty acid synthesis pathway 
comes to a halt, the malonyl-CoA concentration falls, CPT1 becomes uninhibited, and 
fatty acids reaching the liver enter the β-oxidation pathway to form ketone bodies.  
 The molecular mechanisms regulating these events have increased our 
understanding of the methods used to exert control over metabolic pathways. Regulation 
occurs through allosteric control of proteins, reversible phosphorylation, and expression 
of key enzymes through transcriptional regulation of hormone receptors.  Multiple 
isoforms of glucose transporters (GLUT1-4) exist with differing kinetic properties. The 
discovery that certain fatty acids can exert transcriptional effects by binding to the 
nuclear hormone receptor family of peroxisome proliferator-activated receptors (PPARs) 
adds a new dimension in regulating lipid metabolism by mediating long term effects on 
substrate metabolism. The PPAR isoforms (PPARα, -β, -γ) are differentially expressed 






Fig.  1-8. Mechanism of inhibition of glucose utilization by fatty acid 
oxidation.  The extent of inhibition is graded and most severe at the level of 
pyruvate dehydrogenase (PDH) and less severe at the level of 6-phosphofructo-
1-kinase (PFK) and glucose uptake. PDH inhibition is caused by acetyl-CoA and 
NADH accumulation resulting from fatty acid oxidation, whereas PFK inhbition 
results from citrate accumulation in the cytosol. The mechanism of inhibition of 
glucose uptake is not clear. These effects reroute glucose toward glycogen 
synthesis and pyruvate to anaplerosis and/or gluconeogenesis. CYTO, cytosol; 
MITO, mitochondria; GLUT4, glucose transporter 4; HK, hexokinase; Glc-6-P, 
glucose 6-phosphate; Fru-6-P, fructose 6-phosphate; CPT I, carnitine 
palmitoyltransferase I; β-ox, β-oxidation. Hue L , and Taegtmeyer H Am J 







For example, PPARα is expressed mainly in the liver, kidney, heart, and muscle and 
stimulates the transcription of genes that are involved in fatty acid uptake and 
mitochondrial and peroxisomal β-oxidation of fatty acids.  PPARα also affects glucose 
metabolism by increasing PDK4 mRNA and protein to inhibit PDH activity and keeping 
glucose oxidation levels low in the fasted state.  
Fig 1-9.  Mechanism of inhibition of fatty acid oxidation by glucose.  This 
mechanism is mediated by malonyl-CoA, the concentration of which depends on 
ACC activity and which inhibits the entry of long-chain fatty acyl (LCFAcyl-CoA) 
moieties into mitochondria. This effect reroutes fatty acids toward esterification. In 
extrahepatic tissues, the effect of glucose is stimulated by insulin. ACL, ATP-
citrate lyase; FAS, fatty acid synthase. Hue L , and Taegtmeyer H Am J Physiol 
Endocrinol Metab 2009;297:E578-E591. 
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 AMP-activated kinase (AMPK) has also come to be recognized as a mechanism 
involved in the cell’s energy sensing ability. AMPK is expressed in multiple tissues and 
is activated by metabolic stresses, such as a decrease in glucose supply or oxygen 
deprivation, or an increase in energy demand, such as exercise. These stresses increase 
cytosolic concentrations of AMP to rise, altering the [AMP/ATP] ratio.  Changes in 
[Ca
2+
] can also activate AMPK and involves pathways that change intracellular calcium 
levels.  Exercise stimulates AMPK activation in the skeletal muscle to regulate energy 
balance by turning on ATP generating pathways (fatty acid oxidation and glycolysis), 
while switching off ATP consuming pathways (lipid and protein synthesis). AMPK 
phosphorylates and inactivates its substrate, ACC to lower its enzymatic activity, 
allowing malonyl-CoA concentration levels to fall by the decarboxylation activity of 
MCD. This process allows the skeletal muscle to oxidize fatty acids and produce ATP, 
providing favorable conditions for the muscle to adapt to the exercise induced stress 
response.  
 The mechanisms involved in regulating metabolic fuel switching are still evolving 
and the breadth of contribution to these cycles by enzymes, energy substrates, 
transcription factors, and genes require a substantial discussion on the topic, that is 
beyond the scope of this thesis. Overall, metabolic fuel switching involves regulation of 
glucose, lipid, and protein metabolism to allow tissues to adapt to changes from the 
environment with the appropriate use of substrates. The inability to promote metabolic 
fuel switching in insulin responsive tissues has been proposed to be a cause for the rise in 
insulin resistance. Exactly how these mechanisms work in mediating insulin resistance 
still remains unclear. 
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Development of chemical genetic approaches to study metabolism 
 Our increased understanding of biology stems from the ability to alter biological 
mechanisms by perturbing the function of genes, proteins and enzymes. This is usually 
accomplished by the use of traditional pharmacological inhibitors, genetic manipulation 
of genes in transgenic mice, and RNA interference (RNAi).  Each method diverges at 
levels of complexity, timescale of perturbation, and efficiency. With the development of 
new methods, researchers are given more flexibility and control in their research design.  
Chemical genetics is defined as the study of biological systems using small molecule 
tools. Small molecules are advantageous tools because they can be designed to be cell 
permeable, selective, function rapidly and reversibly. These approaches provide excellent 
temporal and quantitative control to study biological processes. 
 Chemical genetic approaches afford great versatility in the field of metabolism. 
Traditional approaches used to study metabolic perturbations have involved homologous 
recombination techniques in mice that enable protein regulation through mutations, 
transcriptional control through RNAi, or viral mediated gene delivery. These approaches 
have their limitations. In some cases, genetic attenuation, mutations, and gene knock-outs 
in mammals are embryonic lethal or have detrimental outcomes during early 
development that prevent full characterization of animal physiology, particularly at later 
stages of life.  RNAi techniques are problematic because they are temporary and changes 
in mRNA levels do not always correspond to changes in protein levels. Viral mediated 
gene delivery methods (adeno-associated virus, lenti virus, retrovirus, etc) are transient, 
not cell specific and are prone to transfection inefficiency.  Because the study of 
metabolic regulation in whole animal physiology relies on secreted hormone factors, cell-
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cell interactions, and multiple isoenzymes, identifying sophisticated methods for 
controlling the level of any protein with fine tuned precision is necessary. Mediating 
protein regulation in metabolism with the small molecule technology of chemical 
genetics, any protein can be targeted for study with tissue and cell specificity, with 
reversibility of activation. 
 
Overview of Shield-1 Chemical Genetics System 
 Technology that provides the ability to rapidly and reversibly alter protein 
function is very desirable to our research investigations. We have made great use of the 
chemical genetic system developed in the laboratory of Dr. Thomas J. Wandless 
(Stanford University) based on Shield-1 regulation of a mutant FK506- and rapamycin –
bindg protein 12 (FKBP12) to achieve synthetic posttranslational protein stabilization 
(51). The system utilizes the synthetic chemical ligand, Shield-1 designed to bind to a 
mutant form of the human FKBP12 protein. Specificity of the Shield-1 ligand to the 
mutant FKBP12, by conferring selectivity over the non-mutant form of FKBP12, 
eliminates the problem of off target effects, endemic to traditional pharmacology. The 
mutant FKBP12 contains two mutations. The first mutation at L106P renders the protein 
most unstable and targets it for degradation by the proteosome. The second mutation 
(F36V) allows the binding of Shield-1 to the mutant FKBP12 and stabilizes the mutant 
FKBP12. Now referred to as a “destabilizing domain,” the mutant FKBP12 is fused to a 
protein of interest (POI). FKBP12 was chosen as a destabilizing domain because its small 
size, feasibility for developing high affinity ligands, and being a highly studied protein 
through its binding to the cellular growth and homeostasis regulator, mTOR. Therefore, 
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the Shield-1 mutant FKBP12 system permits conditional control over protein stability 
upon addition or removal of the Shield-1 ligand (Figure 10). Fusing the mutant FKBP12 
to a fluorescent tag, such as yellow fluorescent protein (YFP), provides a direct 
visualization of stabilization upon by Shield-1. The system has been shown to be 
effective in driving conditional and reversible protein control in mammalian cell culture 







Figure 1-10.  A General Method to Conditionally control Protein 
Stability.  (A) Genetic fusion of a destabilizing domain (DD) to a protein 
of interest (POI) results in degradation of the entire fusion. Addition of a 
ligand for the destabilizing domain protects the fusion from degradation. 
(B) Synthetic ligand for FKBP12 F36V, Shield-1. Modified from: Cell 
Volume 126, Issue 5 2006 995 – 1004. 
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Loss and gain-of-function transgenic models are powerful tools for understanding gene 
function in vivo, but are limited in their ability to determine relative protein requirements.  
To determine cell-specific, temporal or dose requirements of complex pathways, new 
methodology is needed.  This is particularly important for deconstructing metabolic 
pathways that are highly interdependent and cross-regulated.  We have combined mouse 
conditional transgenics and synthetic posttranslational protein stabilization to produce a 
broadly applicable strategy to regulate protein and pathway function in a cell autonomous 
manner in vivo. Here we show how a targeted chemical-genetic strategy can be used to 
alter fatty acid metabolism in a recombination and small molecule dependent manner in 
live behaving transgenic mice.  This provides a practical, specific, and reversible means 
of manipulating metabolic pathways in adult mice to provide novel biological insight. 
 
HIGHLIGHTS  
 Simple, broadly applicable method for regulating metabolic proteins and 
pathways 
 Method produces mice that have dually regulated enzyme expression 
 Affect function in live mice that is gene specific, reversible, and dose-dependent 










 Metabolic pathways are highly interconnected and interdependent. They also 
exhibit remarkable plasticity that can be easily mistaken for or complemented by 
redundancy. Understanding these complexities requires specific temporal and reversible 
pathway perturbation. This is often done using rather nonspecific pharmacology. Ideally, 
one could use small molecules to selectively and potently alter enzyme activity in an 
allele-specific manner by means that would require little knowledge of the reaction 
mechanism. The technique would therefore be straightforward and broadly applicable 
and would occur posttranslationally. 
 There is great interest in the development of small molecules that regulate the 
function of user-engineered proteins (56-60), particularly in the context of intact 
organisms (61-64). Recently, there has been considerable progress in the development of 
small stabilizing or destabilizing protein domains that interact with well-defined inert 
small molecules (51, 52, 65-68). Natural or synthetic small-molecule ligands are chosen 
that interact with specific proteins to either promote or inhibit their rapid posttranslational 
degradation (69). Fusion of a protein of interest to these domains creates a small-
molecule-regulated protein whose function is dose-dependent and reversible. Here, we 
have combined ligand-inducible protein stabilization with genetically tractable 
recombination-mediated transgene expression to enable the targeted small-molecule 
regulation of enzyme activity in live mice.  In order to utilize this strategy to study 
metabolites in vivo, we developed a transgenic vector that allows the small-molecule 
regulation of malonyl-CoA decarboxylase (MLYCD) after Cre-mediated recombination. 
 29 
MLYCD was chosen because its substrate, malonyl-CoA, represents a central metabolic 
node in fatty acid biochemistry. Malonyl-CoA is the product of the rate-setting step in de 
novo fatty acid metabolism, is the substrate for fatty acid synthesis and elongation, and 
allosterically inhibits the rate-setting step in fatty acid beta-oxidation (8). Therefore, 
exerting control over malonyl-CoA through MLYCD has broad experimental utility. This 
approach is not limited to MLYCD but is broadly applicable to other enzymes and genes. 
RESULTS 
Design of a Small-Molecule-Regulated Malonyl-CoA Decarboxylase 
 In order to produce dose-dependent, small-molecule-regulated posttranslational 
stabilization, Wandless et al. constructed a modified FK506 binding protein 12 (FKBP12) 
that binds to and is reversibly stabilized by a synthetic, biologically inert small molecule, 
Shield-1 (51, 52, 70). We made several modifications to the FKBP12-based 
destabilization vectors. A picornavirus PTV1-2A peptide-linked mCherry was fused in-
frame after an FKBP-eYFP destabilization fusion protein and then cloned into an 
MMLV-based selectable retroviral vector (Figure 2-1A). The 2A peptide allows two 
proteins to be produced from a single mRNA at a 1:1 stoichiometric ratio, enabling a 
ratiometric, autonomous measurement of stabilization and localization within cells (71, 
72). Malonyl-CoA decarboxylase (MLYCD) was then cloned as a C-terminal fusion with 
FKBP-YFP flanked by two short flexible linkers. Fusion of the mutant FKBP12 to YFP 
linked to MLYCD allows real-time visualization of Shield-1-induced stabilization. The 
N-terminal mitochondrial localization domain and C-terminal peroxisomal targeting 
sequences were removed from MLYCD to facilitate cytoplasmic MLYCD activity (73). 
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Two stable HEK293T stable cell lines were produced that express FKBP12-eYFP-
MLYCD-2a-mCherry (FY-MLYCD) or FKBP12-eYFP-2a-mCherry (FYFP) to conduct 
an initial characterization of this system in vitro. Shield-1 was synthesized as previously 
reported (51, 74). 
 In order to verify that the stable cells expressed mCherry constitutively and eYFP 
in a Shield-1-dependent manner (Figures 2-1A–1D), stable cell lines were treated with 
Shield-1 for 16 hr. Addition of Shield-1 induced FYFP and FY-MLYCD in a dose-
dependent manner (Figures 2-1C and 1D). To determine the kinetics of stabilization, 
stable cells were incubated with Shield-1 and collected at the designated time points. 
Saturation of stability was achieved 12 hr posttreatment (Figure 2-1E). Likewise, we 
conducted a washout experiment to determine the kinetics of destabilization. Stable cells 
returned to basal stabilization levels 48 hr after Shield-1 removal (Figure 2-1F). These 
data show that Shield-1 induced MLYCD stabilization in a dose-dependent and reversible 
manner. 
 To demonstrate that the FY-MLYCD fusion protein was enzymatically active, we 
treated FY-MLYCD stable cells with Shield-1 or vehicle control for 16 hr. Indeed, 
Shield-1 induced an ∼4-fold increase in MLYCD activity (Figure 2-2A). In a second 
experiment, increasing amounts of Shield-1 were added to FY-MLYCD cells and then 
the cells were assayed for 
3
H-acetate incorporation into lipids, a measure of de novo fatty 
acid synthesis. Addition of Shield-1 resulted in a dose-dependent suppression of de novo 
fatty acid synthesis, demonstrating that FY-MLYCD was enzymatically active and its 
activity was regulated by Shield-1 in a dose-dependent manner (Figure 2-2B). These 
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experiments show that the fusion of the mutant FKBP12 to MLYCD maintained an active 
enzyme that can be regulated by Shield-1. 
 
Dual Chemical and Genetic Regulation of Fatty Acid Metabolism In Vivo 
 Shield-1 has been shown previously to be active when injected into mice, either 
intravenously or intraperitoneally, in a tumor xenograft model to regulate secreted fusion 
proteins in vivo (52). Given the success of Shield-1 in mice, we proceeded to modify this 
technology into a genetically tractable and targeted in vivo mammalian expression 
system to affect metabolism in live behaving mice. The vector was designed to enable the 
conditional targeted expression of a Shield-1-regulated cassette in transgenic mice. A 
lox2272-flanked eCFPcaax stop cassette was cloned into a ubiquitous mammalian 
expression vector (75). Lox2272 was chosen because it does not recombine with 
traditional loxP sequences used in most conditional knockout (KO) mice (76). The FY-
MLYCD transgene was cloned downstream of the floxed stop cassette (Figure 2-3A). 
FY-MLYCD is produced only after Cre-mediated excision of the eCFP stop cassette. 
Transgenic mice expressing Lox2272-eCFPcaax pA Lox2272-FKBP12-eYFP-MLYCD-
2a-mCherry (Tg-fMCD) were produced and characterized for eCFP expression by 
Western blot and direct epifluorescent visualization in cryosections. CFP expression was 
the highest in the muscle, pancreas, and kidney with little to no expression in the brain 
and liver (Figure 2-3B). These mice were then crossed to mice that ubiquitously express a 
tamoxifen-inducible Cre recombinase, CRE
ERT2
 (77) to produce double-transgenic mice 
(Tg-fMCD
ERT2
) in order to initially characterize the Shield-1-inducible system in multiple 
tissues. These Shield-1-regulated transgenic mice can be bred to any transgenic Cre-
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recombinase-expressing mouse to achieve tissue specificity or temporal regulation with 
inducible Cre mice, or both. The flexibility of having dual inducible systems is 
particularly beneficial in cases where the induction of genes is desired in both a cell-
specific and temporal manner. This transgenic vector can be easily tailored to meet 
individual needs. 
 Primary mouse embryonic fibroblasts (MEFs) were derived from double-
transgenic mice. The MEFs exhibited membranous eCFP expression as a marker for 
transgene expression. The addition of 4-hydroxy-tamoxifen resulted in recombination and 
expression of mCherry (marker for recombination), but not of FY-MLYCD (Figures 2-
3C and 3F). Addition of Shield-1 resulted in the expression of cytoplasmic FY-MLYCD 
(Figure 2-3F) in a dose-dependent manner (Figure 2-3C). We conducted kinetic studies to 
determine the stabilization of FY-MLYCD after 4-hydroxy-tamoxifen and Shield-1 
addition. Peak stabilization was reached at 24 hr (Figure 2-3D), while washout studies 
showed that MEFs returned to basal stabilization levels 96 hr after Shield-1 removal 
(Figure 2-3E). These results demonstrate that MLYCD is dually regulated by Cre-
mediated recombination and Shield-1 ex vivo. 
 Next, we tested this dual regulatory system in vivo. Tg-fMCD
ERT2
 animals were 
injected four times with 200 mg/kg intraperitoneal (i.p.) tamoxifen over 1 week to induce 
recombination of the eCFPcaax domain in vivo. After a 48 hr rest period, mice received 
three i.p. injections of Shield-1 at 10 mg/kg at 12 hr intervals. Transgene expression was 
assessed by the expression of membranous eCFP (Figure 2-4A). Recombination was seen 
in vivo as the expression of untargeted mCherry. Stabilization was visualized by the 
expression of cytoplasmic eYFP. Little to no expression of eYFP can be seen in the 
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absence of Shield-1 (Figure 2-4A). Destabilization occurs robustly in vivo, as almost no 
expression was seen in the absence of Shield-1. mCherry and eYFP expression fully 
overlapped. No cells were observed expressing eYFP in the absence of mCherry 
expression. Shield-1 stabilized FY-MLYCD in tissues that express the transgene, 
including the pancreas, skeletal muscle, heart, and adipose tissue (Figures 2-4B–4E). The 
Tg-fMCD
ERT2
 mice exhibited dual regulation of FY-MLYCD in multiple tissues. 
 Finally, we tested the ability of Tg-fMCD
ERT2
 mice to alter the oxidation of fatty 
acids in live mice. Two genotypes were chosen, Tg-fMCD
ERT2
 and control Tg-fMCD 
mice. Tamoxifen was administered to all mice as described above to mediate 
recombination and expression of the FYMLYCD transgene in Tg-fMCD
ERT2
 mice. Mice 
were then given either Shield-1 or vehicle as above. The mice were then assayed 
individually for their ability to fully oxidize radiolabeled palmitate to CO2. Shield-1 had 
no effect on control mice, however, Shield-1 induced an ∼3-fold increase in fatty acid 
oxidation in the fed state (Figure 2- 5). This is approximately the increase in fatty acid 
oxidation seen during prolonged fasting (44). Here, we were able to achieve robust 
changes in the metabolism of fatty acids in live mice using an inert small molecule while 
simultaneously using wild-type littermates to control for any potential off-target effects 
of the chemical. These experiments provide the proof of principle for a broadly 
applicable means to alter protein and metabolic function in vivo. 
 
Tissue-Specific and Dose-Dependent Small-Molecule Regulation of Malonyl-CoA 
Decarboxylase In Vivo 
 The ubiquitous tamoxifen-inducible Cre-recombinase-expressing mouse used 
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above has the advantage of temporal (chemical) and ubiquitous control of recombination. 
These mice were useful for monitoring basic pharmacodynamics of stabilization in 
multiple tissues, as well as permitting mosaic recombination to serve as an additional 
internal cell-autonomous control (Figure 2-4A). This approach is not ideal, however, for 
dissecting tissue-specific effects of metabolic pathways in the context of whole-animal 
physiology. To test this system in a tissue-specific context, we crossed our transgenic 
mice (Tg-fMCD) to mice expressing Cre recombinase from the human alpha-skeletal 
muscle actin promoter (78) (Tg-fMCD
skel
). The expression of the muscle-specific Cre 
recombinase resulted in the deletion of eCFPcaax in muscle without deletion in 
nonparenchymal tissue, as expected (Figure 2-6A). This strategy resulted in a more 
uniform expression of the transgene as assessed by mCherry expression. Again, the 
administration of Shield-1 to Tg-fMCD
skel
 mice resulted in the induction of eYFP-
MLYCD that increased with an increasing dose of Shield-1 (Figure 2-6B). These 
experiments show the utility of this method for modifying protein stability in a tissue-
specific and dose-dependent manner in live mice. 
 
DISCUSSION 
 Here, we have combined inducible protein stabilization with Cre-mediated 
conditionally targeted mouse transgenics to produce a broadly applicable and 
straightforward chemical-genetic strategy to affect metabolism in vivo. Chemical biology 
and chemical genetic techniques have been developed to probe the function of proteins 
in situ in a protein-/gene-specific manner (56-64). The use of designer small molecules 
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that can acutely but specifically control the function of targeted, but not native, proteins 
have advantages in basic science over classical pharmaceutical approaches. The 
specificity of small molecules for their targets is inversely proportional to their 
popularity. In other words, all small molecules have off-target effects that are sometimes 
not appreciated decades after their introduction. In the clinic this can be advantageous or 
catastrophic (79). In basic science, these effects can be misleading in the absence of 
target-specific control experiments in knockout mice, which are rarely feasible. Designer 
drug-target interactions while not useful in the clinic, can be more exquisitely controlled 
in a laboratory setting. 
 The transgenic approach we have designed contains several built-in controls to 
allow direct visualization of stabilization, recombination, and cellular localization 
simultaneously. The addition of lox2272 sites makes this approach ideal for adding back 
wild-type or mutant proteins that have been conditionally knocked out using the more 
common loxP recombination sites. Lox2272, while still being recognized by Cre 
recombinase, does not efficiently recombine with LoxP, thus mitigating genomic 
rearrangement. Ideally one could temporally add back a protein into the same tissue it 
was deleted from and control its function via Shield-1-induced stabilization or 
destabilization. This approach would be ideal for lethal null alleles or highly 
compensated pathways. Furthermore, other orthogonal methods can be used in 
conjunction with this system to achieve multiple modes of regulation in vivo (66, 68, 80). 
 This simple recombination-based system has the advantage of rapid development, 
cost effectiveness, and versatility compared to more laborious knockin strategies. The 
production of mice expressing transgenes is relatively straightforward and accessible to 
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most researchers. Transgenesis combined with recombination-mediated transgene 
activation additionally takes advantage of the large number of publically available tissue-
specific CRE-expressing mouse lines. Therefore, one can target gain-of-function or gene 
replacement to specific cell types to better dissect tissue-specific roles of ubiquitous 
genes. Making knockin mice enables the endogenous expression of genes but does not 
make it possible to discern tissue-specific effects. Tissue-specific promoters would 
satisfy this as well but are not versatile in directing transgenes to different cell types. The 
methodology here is beneficial in cases where one may need to produce several groups of 
mice to examine, for example, the relative role of enzymes in multiple tissues. 
 Low-abundance, structurally similar metabolites can be onerous to functionally 
elucidate within the context of mouse physiology, particularly when defining cause-and-
effect relationships. The technique described here has the potential to intimately dissect 
metabolic pathways in living mice to better understand the relationship between 
metabolites and metabolic pathways and disease in distinct cell types. For example, 
acetyl-CoA carboxylases alpha (ACACA) and beta (ACACB) have been assigned 
differential roles in directing fatty acid metabolism, but these roles have become unclear 
of late (81-84), presumably due to compensation by these closely related enzymes. 
Altering specific metabolites in a cell-specific and temporal manner will offer a more 






This mode of posttranslational control over protein stability has the advantage of quick 
kinetics, dose responsiveness, and reversibility similar to that of small-molecule 
pharmacology, with the added benefit of allele specificity. This simple, single-vector 
approach to making double-conditional transgenic mice provides a flexible platform to 
more precisely refine protein function in vivo. Furthermore, the reaction mechanism does 
not need to be known, and large-scale chemical screening does not need to be preformed. 
Therefore, new proteins or structurally similar protein families can be targeted to 
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The FKBP12 destabilizing domain construct was fused to eYFP and a murine malonyl-
CoA decarboxylase cDNA. Several modifications were made to the MLYCD cDNA prior 
to fusion with FKBP12-YFP: the mitochondrial and peroxisomal targeting signals were 
removed with the addition of flexible GSG linkers to the N and C termini of MLYCD. 
Next, a viral 2A bicistronic peptide was fused in frame linked to the red fluorescent 
protein mCherry to follow cellular localization. The construct and control (lacking 
MLYCD) were cloned into the retroviral vector, pLPCx (Clonetech), by standard 
methods. 
Generation of HEK293 Stable Cell Lines Expressing FKBP12-YFP-MLYCD-2A-
mCherry 
HEK293T cells were grown in DMEM containing 10% FBS and 1% pen/strep 
(Invitrogen) at 37°C in a humidity-controlled chamber at 5% CO2. To produce stable cell 
lines, HEK293T cells were infected with the retroviral constructs. Stable cell lines were 
produced by antibiotic selection with puromycin. 
Generation of Transgenic Mice 
A lox2272-flanked eCFP caax STOP SV40 polyA cassette was produced by PCR using 
standard methods and cloned into the pCAG vector (addgene #13787) (75, 85). The 
FKBP12-YFP-MLYCD-2A-mCherry transgene was cloned downstream of a Lox 2272 
CFP STOP Lox2272 cassette driven by the ubiquitous CMV-enhanced chicken beta actin 
promoter (CAG). The transgenic vector was injected into pronuclei of fertilized zygotes 
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(B6SJLF1) at the Johns Hopkins University School of Medicine Transgenic Mouse Core 
Facility. Transgenic founders and germline transmitters were identified by testing for the 
expression of CFP by PCR genotyping. We crossed the resulting Tg-fMCD transgenic 
mouse to a transgenic line that expresses a CRE
ERT2
 inducible by tamoxifen (B6;129S-
Tg(UBC-cre/ERT2)1Ejb/J) (77) to study the temporal regulation of MLYCD expression 
(referred to as Tg-fMCD
ERT2
) or to mice expressing Cre from a muscle-specific promoter 
(B6.Cg-Tg(ACTA1-cre)79Jme/J) (78) (referred to as Tg-fMCD
skel
). Cre-mediated 
excision of eCFP is confirmed by genotyping PCR. All procedures were performed in 
accordance with the National Institutes of Health Guide for the Care and Use of 
Laboratory Animals and under the approval of the Johns Hopkins Medical School 
Animal Care and Use Committee. 
Assay for De Novo Fatty Acid Synthesis 
Stably transfected HEK293T cells expressing FY-MLYCD were plated at a density of 
4 × 10
5
 cells in a 24 well plate (n = 6) and stimulated with Shield-1 or vehicle at 
increasing concentrations for 18 hr. Cells are labeled with 1.0 μCi of [
3
H] acetic acid 
acetate (Perkin Elmer) for an additional 2 hr. Total lipids are extracted with 
chloroform/methanol and counted via liquid scintillation. 
Malonyl-CoA Decarboxylase Assay 
A fluorimetric assay that measures the formation of acetyl-CoA from malonyl-CoA, 
coupled with citrate synthase and malate dehydrogenase, was used to determine MCD 
activity in stable HEK293 T cells expressing FY-MLYCD (86). Cells were plated at a 
density of 1 × 10
6
 cells in a 10 cm plate, then stimulated with Shield-1 or vehicle for 
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24 hr. Cells were harvested with an extraction buffer (0.1 M Tris, pH 7.4, containing 
1 mM dithiothreitol (DTT), protease, and PhosStop inhibitors cocktail (Roche)) followed 
by a brief sonication. Cells were pelleted by centrifugation at 13,000 × rpm (30 min at 
4°C) and supernatants were transferred to new Eppendorf tubes. Protein estimation was 
determined using the Pierce BCA Protein Assay Kit, and 0.5 mg of protein was used to 
carry out a partial purification of MCD by (NH4)2SO4. To the lysates, 3.8 M (NH4)2SO4 
was slowly added on ice with vortexing, until 60% saturation was reached. The mixture 
was allowed to precipitate overnight at 4°C followed by centrifugation at 13,000 × rpm 
(60 min at 4°C). The pellets were resuspended in 0.1 M Tris-HCl (pH 8.0). MCD activity 
was measured using a Synergy MX multimode microplate reader (BioTek Instruments, 
Inc.) with excitation and emission wavelengths set to 340 and 460, respectively. Reaction 
mixtures of 140 μl containing 0.1 M Tris-HCl (pH 8.0), 0.5 mM DTT, 10 mM L-malate, 
0.5 mM NAD, and 17 units of malate dehydrogenase were incubated for 7 min at 37°C in 
a 96 well black flat-bottom assay plate. A baseline-fluorescence measurement was 
followed by the addition of citrate synthase (3.14 units), succeeded by an additional 
2 min incubation. Malonyl-CoA (0.3 mM) was added, followed by 20 μl of the 
(NH4)2SO4-purified sample fraction. The incubation was allowed to continue for an 
additional 7 min before a second measurement for the rate of formation of NADH was 
taken. 
In Vivo Fatty Acid Oxidation 
In vivo oxidation of 1-
14
C palmitic acid was measured in mice by i.p. injection of labeled 
palmitate (1 μCi) bound to fatty-acid-free bovine serum albumin, as previously reported 




collected by bubbling the collected gas through 1 N NaOH. An aliquant of NaOH was 
measured by scintillation counting every 15 min for 45 min. 
Western Blots 
Whole tissues or stable HEK293T cells were harvested and total protein was extracted 
with sonication in extraction buffer (1% (v/v) Nonidet P-40 in TBS (50 mm Tris-HCl, pH 
7.5, 150 mm NaCl) with protease and PhosSTOP phosphatase inhibitors cocktail 
(Roche). Cellular debris was pelleted at 13,000 × rpm (30 min at 4°C). Protein 
concentration was estimated using the Pierce BCA Protein Assay Kit. Soluble proteins 
(25 or 50 μg) were separated using Bio-Rad Tris Glycine SDS-PAGE gels (8%) or 
Invitrogen BisTris SDS-PAGE gels (4%–12%). Proteins were transferred to 
nitrocellulose membranes, blocked in 3% nonfat milk and detected by immunoblotting 
with antibodies to FKBP12 (Thermo Scientific), dsRED (Clonetech), MLYCD (abcam), 
and Heat shock Protein 8 (HSC-70) (Santa Cruz Biotechnology). HRP was detected using 
Immobilon Western Chemiluminescent substrate (Millipore Corporation, Billerica, MA) 











Figure 2-1 Small molecule induced enzyme stabilization.  (A) An FKBP12 
destabilization domain that is inducibly stabilized by the small molecule Shield-1 was 
fused to eYFP and Malonyl-CoA Decarboxylase (MLYCD).   The inducible MLYCE is 
linked to a constitutively expressed mCherry via a bicistronic viral PTV1-2A peptide. (B) 
Epifluorescent images of Shield-1 stabilized MLYCD and constitutive expression of 
mCherry in HEK 293T cells.  Western blots of dose-dependent Shield-1 induced 
stabilization of (C) control and (D) MLYCD HEK 293T cells. (E) Time course and (F) 







Figure 2-2.  Shield-1 regulated Malonyl-CoA Decarboxylase activity.  (A) Shield-1 
induces MLYCD activity.  (B) Shield-1 suppresses de novo fatty acid synthesis in a dose-
dependent manner as measured by 
3
























Figure 2-3. Dual chemical regulation of protein stability. (A) The 
destabilizationcassette was cloned downstream of a Lox2272 eCFPcaax Stop cassette 
driven by the ubiquitous CMV-enhanced chicken beta actin promoter (CAG). Cre-
mediatedrecombination between the Lox sites excises the eCFPcaax Stop cassette and 
express the FKBP12-YFP-MLYCD-2A-mCherry cassette. (B) Differential eCFP tissue 
expression in transgenic mice as shown by Western blot. (C) Western blot of MEFs from 
double conditional Tg-fMCDERT2 mice. Isolated MEFs were treated with 500nM 4-
hydroxytamoxifen (4HT) and Shield-1 or vehicle control and blotted for FKBP12 
(stabilization), mCherry (recombination), and HSC 70 (loading control). (D) Time course 
and (E) washout stabilization of MLYCD. (F) Epifluorescent images of tamoxifen 
















Figure 2-4. Figure 2-4. Chemical genetic regulation of MLYCD in vivo. (A) 




followed by Shield-1 (10mg/kg) or vehicle control. (B) Western blots of FY-MLYCD 


















Figure 2-5. Chemical genetic regulation of fatty acid metabolism in vivo. Live mouse 








Figure 2-6. Tissue-specific and dose-dependent regulation of protein stability in vivo.  
(A) Images of Shield-1 stabilization in the skeletal muscle of conditionally regulated 
TgfMCDskel mice by fluorescent confocal microscopy. Animals were injected with 
Shield-1 (20 mg/kg) or vehicle control. (B) Western blot of Shield-1 dose-dependent 
stabilization in the skeletal muscle of Tg-fMCDskel and control mice. Animals were 
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 Defects in skeletal muscle fatty acid oxidation have been implicated in the 
etiology of insulin resistance. Malonyl-CoA decarboxylase (MCD) has been a target of 
investigation because it reduces the concentration of malonyl-CoA, a metabolite that 
inhibits fatty acid oxidation. The in vivo role of muscle MCD expression in the 
development of insulin resistance remains unclear. To determine the role of MCD in 
skeletal muscle of diet induced obese and insulin resistant mouse models we generated 
mice expressing a muscle specific transgene for MCD (Tg fMCD
Skel
) stabilized 
posttranslationally by the small molecule, Shield-1.  Tg fMCD
Skel
 and control mice were 
placed on either a high fat or low fat diet for 3.5 months. Obese and glucose intolerant as 
well as lean control Tg fMCD
Skel
 and nontransgenic control mice were treated with 
Shield-1 and changes in their body weight and insulin sensitivity upon induction of MCD 
were determined. Two weeks of MCD induction did not improve body weight or 
glycemic control in obese Tg fMCD
Skel  
mice. In obese Tg fMCD
Skel
 mice, skeletal 
muscle insulin-stimulated AKT phosphorylation was decreased compared to obese 
nontransgenic controls. In addition, skeletal muscle specific expression of MCD 
decreases the protein and mRNA abundance of oxidative metabolism genes compared to 
obese controls. Acute induction of skeletal muscle MCD in obese and glucose intolerant 
mice did not improve body weight and decreased insulin sensitivity compared to obese 
nontransgenic controls.  However, induction of MCD in skeletal muscle resulted in a 
suppression of mitochondrial oxidative genes suggesting an unexpected redundant and 




 The concomitant rise in obesity and type 2 diabetes has mustered a global effort to 
understand the links between nutrient overload and insulin resistance to enable new 
therapies. The skeletal muscle plays an important role in maintaining systemic glycemic 
control by mediating a majority of insulin stimulated glucose disposal.  Skeletal muscle 
has been demonstrated to be a primary tissue driving insulin resistance and is the target 
for several anti-diabetic drugs (87-89).  Excess lipid accumulation outside of adipose 
tissue is thought to contribute to diabetes by engaging pathways that inhibit insulin 
signaling. The mechanisms that lead to the development of lipid induced insulin 
resistance remain elusive, but consistent themes converge at pathways implicating 
inflammation, ER stress, and mitochondrial insufficiency (12, 15, 16, 90). 
 Skeletal muscle with its high capacity for fatty acid oxidation has been a focal 
point for genetic and pharmacological studies aimed to restore lipid balance by promoting 
lipid oxidative pathways. Mitochondria are the major site for fatty acid oxidation and 
defects in this process may contribute lipotoxic pathways.  The lipotoxicity hypothesis 
suggests that accumulation of lipid signaling intermediates interact and disrupt insulin 
signaling to mediate or exacerbate insulin resistance (91-95).  The finding that the 
muscles of patients with type 2 diabetes contained fewer and smaller mitochondria than 
those of age matched insulin sensitive controls, further supported the concept that 
mitochondrial deficiency or dysfunction is a driver of insulin resistance (96-102).  The 
muscle’s decreased mitochondrial content limits its capacity to oxidize fatty acids, 
resulting in the accumulation of undesirable intramuscular lipids, such as ceramide, TAG, 
and DAG.  Therefore, methods that increase fatty acid oxidation akin to exercise, in the 
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muscle to relieve the toxicity caused by these lipid intermediates have been sought to 
improve insulin resistance. 
 Malonyl-CoA is the substrate for de novo fatty acid synthesis and its 
concentration is dependent on the nutritional status of the cell. Malonyl-CoA is produced 
by acetyl CoA carboxylase (ACC) and catabolized by malonyl-CoA decarboxylase 
(MLYCD, commonly referred to as MCD) in the cytoplasm. Although malonyl-CoA is 
the substrate for fatty acid synthase (FAS) for the production of fatty acids de novo, it 
does not occur at high levels in skeletal muscle (103). In the skeletal muscle, MCD 
catalyzes the decarboxylation of malonyl-CoA to enhance fatty acid oxidation as 
malonyl-CoA is the allosteric inhibitor of the rate setting step in mitochondrial long chain 
fatty acid beta-oxidation, Carnitine Palmitoyltransferase 1 (CPT1). Genetic and 
pharmacological studies to inhibit or activate genes involved in fatty acid synthesis 
(ACC2) or oxidation (CPT1, MCD, AMPK) have produced conflicting results into the 
benefits of skeletal muscle mitochondrial fatty acid oxidation in models of diet induced 
insulin resistance (73, 81, 83, 104-107). A whole body deletion of ACC2, to promote fat 
oxidation by decreasing malonyl-CoA levels, produces lean hyperphagic mice. As a 
result, ACC2
-/- 
mice exhibited increased fatty acid oxidation, increased energy 
expenditure and improved insulin sensitivity through AKT2 stimulation (108). The 
potential benefits arising from decreased malonyl-CoA levels to promote fatty acid 
oxidation and reduce body mass to increase insulin sensitivity prompted the development 
of a muscle specific deletion of ACC2 in mice. The tissue specific model produced mice 
that exhibited no protection from obesity or insulin sensitivity compared to the whole 
body ACC2
-/-
 predecessor (83). Over-expression of MCD in the liver of rats fed a high fat 
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diet improved whole body insulin resistance (73). Conversely, the loss of whole body 
MCD resulted in resistance to diet-induced glucose intolerance, in the presence of 
increased skeletal muscle triacylglycerol and long chain fatty acids (107, 109). A study 
using human cultured skeletal myotubes investigated the effects of shifting substrate 
oxidation from lipid to glucose via RNA interference-mediated (siRNA) gene silencing 
of MCD under basal and insulin-stimulated conditions (106).  Reducing MCD expression 
in human myotubes, lead to decreased lipid oxidation of palmitate with a rise in glucose 
oxidation under insulin stimulation. However, these studies are confounded by the loss of 
mitochondrial MCD and the subsequent increase of malonate, a cytotoxic metabolite that 
inhibits succinate dehydrogenase  (110-114). 
 The interconnected nature of metabolic pathways, coupled with the redundancy 
and compensatory effects often seen by over-expression and knockout studies make it 
difficult to tease out the contributions of individual pathways to the pathophysiology of 
insulin resistance in skeletal muscle.  Chemical-genetic techniques have been developed 
to acutely alter metabolic pathways in a manner that is temporal, cell-specific, and 
reversible (51, 52, 55).  We have previously shown the posttranslational regulation of 
MCD in transgenic mice in a tissue specific manner via a biologically inert small 
molecule, Sheild-1 (55). Here, we acutely induced MCD in the skeletal muscle of obese 
and glucose intolerant mice to determine the impact of modulating skeletal muscle fatty 
acid oxidation in a model of diet-induced obesity. A two week induction of MCD in 
skeletal muscle did not alter body weight or ameliorate glucose intolerance, conversely it 
further impaired insulin signaling in the skeletal muscle of diet induced obese mice.   
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Surprisingly, an acute induction of MCD led to suppression of fatty acid oxidative genes 
suggesting a redundant and metabolite driven regulation of gene expression. 
  
RESULTS 
In Vivo Chemical-Genetic Regulation of Malonyl-CoA Decarboxylase in Skeletal 
Muscle.
 
 Lipids mediate insulin resistance in skeletal muscle via an unknown mechanism; 
however, promoting the rate of fatty acid oxidation in skeletal muscle has been proposed 
to effect insulin sensitivity in this tissue (81, 108, 115-119).  Given the importance of 
MCD in regulating skeletal muscle fatty acid oxidation, we generated transgenic mice 
where MCD (Tg-fMCD) can be regulated in a cell and chemical specific manner in order 
to determine the effect of acutely altering fatty acid metabolism in insulin resistance (55, 
81).  A cytoplasmic targeted MCD fused to a destabilization domain was cloned 
downstream of a lox mCherry stop cassette.  Therefore, the expression of the transgene is 
controlled in a Cre-recombinase dependent manner to target transgene expression.  The 
destabilization domain was derivatized from FKBP12 (FK506 binding protein 12) 
enabling reversible and dose dependent protein stabilization from the synthetic ligand 
Shield-1 (51).  In order to target the transgene to skeletal muscle, Tg-fMCD mice were 
bred to mice expressing Cre recombinase from the human alpha skeletal muscle actin 
promoter, ACTA1, producing Tg-fMCD
Skel
 mice.  Thus, we generated mice expressing 
cytoplasmic MCD that can be stabilized by Shield-1 in a skeletal muscle specific manner 
(Fig. 1A). 
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  In order to determine the appropriate dose to achieve effective transgene 
stabilization we injected Tg-fMCD
Skel
 mice with increasing concentrations of Shield-1 in 
corn oil to determine basic in vivo pharmacokinetics and determine the required dose to 
effectively increase MCD.  Shield-1 induced effective transgene stabilization at 20mg/kg 
(Fig. 1B).  We had previously used corn oil to deliver Shield-1 to mice (55).  However, 
since our goal was to determine the effect of lipid metabolism on insulin sensitivity, we 
chose a vehicle that did not contain dietary lipids.  Others have reported in vivo delivery 
of Shield-1 in PEG/Tween/NNMDA (52).  To prevent confounding effects of corn oil, we 
administered Shield-1 at varying doses in PEG/Tween/NNMDA. Injection of 60 mg/kg 
Shield-1 with a PEG/Tween/NNMDA effectively stabilized the MCD transgene (Fig. 
1C).  Therefore we chose 60 mg/kg Shield-1 in a PEG/Tween/NNMDA vehicle to alter 
MCD in mice. 
 
A Two Week Induction of MLYCD in Skeletal Muscle Did Not Alter Body Weight 
or Glucose Sensitivity. 
 To assess whether increased fatty acid oxidation is associated with improvements 
in body weight and insulin sensitivity in a model of diet induced obesity, we made Tg-
fMCD
Skel 
 mice and littermate controls obese and insulin resistant with 12 weeks of high 
fat diet (HFD) (60% kcal from fat) feeding. An additional group of Tg-fMCD
Skel 
mice 
and littermate controls were fed a low fat diet (LFD) (10% kcal from fat) at 7 weeks of 




and control mice on the high fat diet 
rapidly gained weight, and there was no difference between genotypes (Fig 2B). Mice on 
the LFD remained lean throughout the period (Fig 2B).  Glucose sensitivity was 
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examined by preforming glucose and insulin tolerance tests. High fat diet-induced 
glucose intolerance was clearly evident in both genotypes (Fig. 2 C,D). Tg-fMCD
Skel 
  
mice and control mice began with elevated fasting blood glucose levels in the insulin 
tolerance test and failed to clear blood glucose as efficiently as their lean counterparts on 
the LFD (Fig. 2E). Thus, as expected, Tg-fMCD
Skel 
mice in the absence of the inducing 
ligand displayed no protection from obesity or insulin resistance. 
 To gain insight into the role of MCD in regulating metabolic dysfunction in the 
skeletal muscle, we treated Tg-fMCD
Skel
 and control HFD-induced obese and insulin 
resistant mice with Shield-1 (60 mg/kg) or vehicle every 48 hours for 2 weeks. Acute 2 
week Shield-1 treatment did not alter body weight in Tg-fMCD
Skel 
or WT HFD mice 
(Fig. 3A). Moreover, MCD induction did not improve glucose sensitivity of these mice 
(Fig. 3B). Insulin measurements from Tg-fMCD
Skel
 HFD Shield-1 treated mice taken 
during the glucose tolerance test, show no difference in insulin sensitivity compared to 
WT HFD Shield-1 controls; both groups of mice remained insulin resistant compared to 
lean controls. These data suggest that acute induction of MCD in the skeletal muscle is 
not sufficient to alter adiposity or insulin sensitivity.  
 
Acute Induction of MLYCD in Skeletal Muscle Repressed AKT Signaling. 
 To address possible tissue specific insulin sensitivity in the skeletal muscle, we 
performed an in vivo insulin stimulation followed by tissue collection.  HFD fed Tg-
fMCD
Skel
 and WT mice received an acute treatment of Shield-1 at 60 mg/kg every 24 
hours for 5 days. Mice were injected with insulin 24 hours after the last dose of Shield-1 
and gastrocenemius muscle was harvested 10 minutes after the insulin injection. As 
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expected insulin stimulated phosphorylation of AKT Ser 
473 
was decreased in Tg-
fMCD
Skel 
HFD and control HFD mice compared to lean LFD controls (Fig 4A). Tg-
fMCD
Skel
 HFD Shield-1 mice, compared to WT HFD Shield-1 controls, showed a further 
2-fold suppression in insulin stimulated phosphorylated AKT Ser 
473
 relative to total AKT 
in the skeletal muscle (Fig. 4A). To determine the specificity of Shield-1 for the FY-
MCD transgene in the skeletal muscle we showed expression and stabilization of the FY-
MCD transgene by Shield- 1 only in the muscle (Fig. 4A), not in the liver, heart, or 
pancreas of the transgenic mice (Fig. 5A-C). These data suggest that induction of MCD 
in HFD induced insulin resistant skeletal muscle decreased insulin stimulation of AKT 
Ser 
473, 
phosphorylation and this exacerbates insulin resistance.  
 
Induction of MLYCD Suppresses Fatty Acid Oxidation Genes. 
 Previously, we showed that an acute induction of MCD leads to an increase in 
fatty acid oxidation in vivo (55). Because malonyl-CoA and MCD are major regulators of 
skeletal muscle fatty acid oxidation, we examined the effect of inducing MCD on genes 
in the fatty acid oxidation pathway during the development of diet induced obesity and 
diabetes. Surprisingly, Tg-fMCD
Skel 
HFD Shield-1 mice, compared to WT HFD Shield-1 
treated counterparts, had approximately 2-fold reduced protein abundance of CPT1B and 
oxidative phosphorylation complex proteins (Fig 4A).  Due to reduced fatty acid 
oxidation protein expression, we questioned the possible activation of the energy sensor, 
AMPK.  AMPK phosphorylation at Thr 172, the major activating phosphorylation site 
was not changed by MCD induction (Fig. 4B). Moreover, MCD induction did not  alter 
phosphorylation of ACC, a target of AMPK. These data suggest that AMPK and ACC do 
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not play a role in mediating the decrease in insulin sensitivity observed in Tg-fMCD
Skel 
mice (Fig. 4A). 
 Because we observed a decrease in CPT1B and components of oxidative 
phosphorylation complexes 2, 3, and 4, suggesting a decreased capacity for oxidation, we 
determined if the decrease was due to regulation at the transcriptional level.  Gene 
expression analysis of gastrocenemius muscle from Tg-fMCD
Skel 
HFD Shield-1  treated 
mice demonstrate a consistent decrease in genes involved in fatty acid oxidation 
compared to vehicle treated HFD controls (Fig. 6). These data demonstrate that an acute 
increase in skeletal muscle lipid oxidation by MCD in a model of obesity induces a 




A growing number of studies have shown a detrimental effect of skeletal muscle 
mitochondrial fatty acid oxidation in diet induced insulin resistance and obesity. We have 
increased MCD to increase fatty acid oxidation in skeletal muscle. Here, we demonstrate 
that 1) induction of MCD did not lead to changes in body weight in HFD induced obese 
mice, 2) an acute induction of MCD augmented skeletal muscle insulin sensitivity in 
HFD induced obese mice, 3) MCD induction resulted in a suppression of oxidative genes 
within skeletal muscle.  The induction of MCD in the skeletal muscle exacerbated the 
diabetic phenotype by negatively effecting insulin/AKT signaling. These data provide 
insight into the pathophysiology of skeletal muscle insulin resistance and shows that 
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inducing MCD to increase fatty acid oxidation does not reverse obesity-induced glucose 
intolerance or adiposity. 
 The role of skeletal muscle mitochondria in the promotion or protection from 
metabolic dysfunction is not well understood.  Based on the strong correlation between 
increased lipid consumption and insulin resistance, some have suggested that the 
accumulation of cytoplasmic lipid intermediates that are often seen in diabetic patients 
and animal models directly impairs insulin signaling (102, 120).  Based on this, and the 
observation that a sedentary lifestyle promotes metabolic dsyfunction, it has been 
suggested that the stimulation of fatty acid oxidation could lower the concentration of 
toxic intermediates to improve insulin sensitivity by removing the lipid substrates.  In 
support of this, individuals with type 2 diabetes and even prediabetes have decreased 
mitochondrial function (96, 101, 121, 122).  However, several mouse models with 
increased lipid oxidation do not have improved insulin sensitivity (104).  Inversely, 
metformin, which is widely used to treat diabetic patients, has been proposed to work as a 
mild electron transport inhibitor (123-125) and mice with decreased fatty acid oxidation 
due to mutations in complex I of the electron transport chain are protected from diet 
induced glucose intolerance.  In support of these findings, we were unable to observe 
improvements in body weight or insulin sensitivity by increasing fatty acid oxidation 
with the overexpression of MCD in our model of high fat diet induced insulin resistance.  
Obesity induced insulin resistance is associated with reductions in fatty oxidation 
genes and mitochondrial dysfunction (126, 127).  Human studies support the observation 
of decreased transcriptional control of fatty acid oxidative genes in the skeletal muscle of 
obese, highly insulin resistant people.  Specifically, individuals in the most insulin 
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resistant and insulin sensitive groups had lowered expression of PGC1α, PPARα, and 
CPT1B (128). A second study described decreased mRNA content in PDK4, PGC1α, and 
PPARα in obese, but not lean individuals (129).  In contrast, small molecule inhibition of 
CPT1 improved insulin sensitivity and increased pyruvate dehydrogenase activity to 
promote glucose oxidation, and AKT phosphorylation (130).  These studies suggest the 
skeletal muscle employs different mechanisms to adapt to varying degrees of insulin 
resistance. The skeletal muscle may use alternate mechanisms to regulate macronutrient 
substrate switching to increase glucose oxidation in a prolonged state of over nutrition. 
(109, 131). 
 Induction of MCD herein indicates that increasing lipid oxidation in the skeletal 
muscle may be a contributing factor in diabetes. Skeletal muscle MCD regulates the 
concentration of malonyl-CoA, the precursor for fatty acid synthesis and elongation. 
Decreasing the concentration of malonyl-CoA, dysinhibits CPT1, the rate-limiting 
enzyme in mitochondrial fatty acid oxidation. Interestingly, acute MCD expression in the 
skeletal muscle down-regulated CPT1B and other genes in the lipid oxidation pathway at 
the transcriptional and protein level (Fig. 5-6). These fatty acid oxidation genes are 
known targets of PPARα transcriptional activation, suggesting a novel mechanism 
linking intermediary metabolism to PPARα transcriptional regulation.  PPARα has been 
shown to play an important role in the transcriptional regulation of lipid and glucose 
metabolism, particularly in skeletal muscle fatty acid oxidation (132). Despite the 
importance of PPARα in guiding human physiology and disease, the identities of natural 
PPAR ligands remain unclear. Metabolites likely play larger roles in regulating genes and 
pathways that have not been appreciated yet. We suggest a possible mechanism where 
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increasing MCD and resulting increased acetyl-CoA and fatty acid intermediates 
generates a metabolic signal that has downstream effects on PPARα mediated 
transcriptional control. 
 Chemical genetics has the potential to unravel metabolite and pathway 
contributions to animal physiology and pathophysiology with a higher resolution because 
it combines the stringency of genetics with the quick kinetics and dose dependence of 
small molecule pharmacology.  Taking a chemical genetic approach in the design of the 
MCD transgene affords several built in controls to regulate in vivo metabolism with the 
benefit of small molecule inhibition and genetic specificity. The MCD transgene allows 
direct visualization of key internal features to control for recombination, localization of 
transgene expression, and transgene activation by Shield-1 (55).  The specificity and 
mechanism of action of Shield-1 for the destabilization domain is well defined and any 
off target effects can be controlled for in Shield-1 treated nontransgenic mice. (51). This 




These results indicate that induction of MCD leads to decreased fatty acid 
oxidation gene expression, impairs skeletal muscle insulin sensitivity, and implicates 
PPARα in a fatty acid induced down regulation of oxidative genes in vivo to regulate the 
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Antibodies and Chemicals- Rabbit polyclonal antibodies that recognize phospho-AKT 
(Ser 473), Pan AKT, phospho AMPK Thr 172, AMPKα, phosph ACC Ser 79, Acetyl-
CoA Carboxylase were obtained from Cell Signaling Technology. Rabbit polyclonal 
antibody detecting endogenous MCD was obtained from Abcam.  A polyclonal antibody 
for dsRED was obtained from Clontech.  Stabilization of Shield-1 was confirmed with a 
rabbit polyclonal antibody for FKBP-12 (Thermo Scientific). MitoProfile total OXPHOS 
Rodent WB Antibody cocktail was obtain from MitoSciences. Alpha-Tubulin protein 
loading control was obtained from Sigma.  Gastrocnemius muscle for tissue analysis of 
signaling proteins, detection of endogenous recombination markers, and stabilization by 
Shield-1 was harvested and immediately flash frozen in liquid nitrogen. Total protein was 
extracted by tissue homogenization in cold lysis buffer consisting of 50 mM Tris-HCl, 
150 nM NaCl, 1mM EDTA, 1% Triton X-100, with protease and PhosStop phosphatase 
inhibitor cocktail (Roche). Tissue homogenates were pelleted at 16,000 g for 30 minutes 
at 4°C and supernatants collected into fresh, cold micro centrifuge tubes. Protein 
estimation by Pierce BCA Protein Assay Kit was used to determine protein concentration 
in supernatants. Proteins were separated using NuPAGE Novex 4-12% Bis-Tris Gels in 
NuPAGE MOPS SDS running buffer. Proteins were transferred to PVDF membranes 
(0.45 μm), blocked in 5% non-fat milk and detected by immunoblotting with the 
antibodies above. HRP-conjugated secondary antibodies were detected using Amersham 
ECL Prime Western Blotting Detection Reagent (GE Healthcare) and detected using the 
FluorChem Western Blot imaging system (Cell Biosciences).  Shield-1 was synthesized 
as previously reported (51, 74). Shield-1 was dried under a stream of nitrogen gas and 
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reconstituted in 50% N,N-dimethyacetamide and 50% of a 9:1 PEG-400:Tween-80 
mixture (52).  Shield-1 was administered intraperitoneally. 
 
Animal studies-  Tg-fMCD mice were bred to mice expressing Cre from a muscle 
specific (human alpha-skeletal actin) promoter obtained from Jackson Laboratory to 
generate Tg-fMCD
skel
 mice (78). Tg-fMCD
skel 
and wildtype littermates were maintained 
on a standard chow diet, with free access to food and water and maintained on a 12 hour 
light-dark photocycle in a temperature controlled environment.  At 6 weeks of age, Tg-
fMCD
skel 
and control littermate male mice were transitioned from a standard chow diet to 
a 60% kcal from fat high fat diet (HFD) (D12492, Research Diets, Inc.) or 10% kcal from 
fat low fat diet (LFD) (D12450J, Research Diets, Inc.). Body weights were measured 
weekly. Onset of glucose intolerance was assessed by glucose and insulin tolerance tests. 
At 19 weeks of age, Tg-fMCD
skel 
and control mice were injected i.p. with 60mg/kg 
Shield-1 (40 μl formulated in 50% N,N-dimethylacteamide and 50% of a 9:1 PEG-
400:Tween-80 mixture) or vehicle alone.  Mice received Shield-1 or vehicle injections 
every 48 hours for 2 weeks. Glucose tolerance tests were repeated on mice to measure 
efficacy of Shield-1 treatment to lower fasting blood glucose and increase insulin 
sensitivity. Mice used for the insulin stimulation studies, were i.p. injected with 60mg/ kg 
Shield-1 or vehicle every 24 hours for 5 days before the stimulation. Acute insulin 
stimulation was performed on mice following a 6 hour fast. Mice were injected i.p. with a 
1U/ kg insulin (Sigma, bovine pancreas) dose. Tissues were collected 10 minutes after 
insulin injection, frozen in liquid nitrogen, and stored at -80°C.  Animal experiments 
were done in accordance with the National Institutes of Health Guide for the Care and 
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Use of Laboratory Animals and under the approval of the Johns Hopkins Medical School 
Animal Care and Use Committee.  
 
Glucose and Insulin Tolerance Testing –Mice were fasted for 6 hours before i.p. 
injection with 1.25 mg/g glucose or 0.8 U/kg of insulin (Sigma) in a 0.9% NaCl solution. 
Blood glucose was assayed from tail blood at times, 0, 15 min, 30 min, 60 min, 120 min 
for the GTT after glucose injection.  Blood glucose was assayed from tail blood at times, 
0, 15 min, 30 min, 60 min after the insulin injection for the ITT. Serum insulin was 
collected at the 15 minute time point during the GTT and measured using a mouse insulin 
ELISA kit (Millipore). 
 
Quantitative real time PCR analysis- - Isolated Gastrocnemius muscles from Tg-
fMCD
skel 
and control male mice were frozen in liquid nitrogen and stored at -80°C until 
homogenization with Trizol (Life Technologies) to isolate RNA.  The conversion of 
RNA to cDNA, was performed by using a high capacity cDNA reverse transcription kit 
(Applied Biosystems). The following PCR primer pairs were used for this study:  
ACOT1 forward, 5’-GACAAGAAGAGCTTCATTCCCGTG-3, 
ACOT1 reverse, 5’-CATCAGCATAGAACTCGCTCTTCC-3, 
CPT1B forward, 5- GGTCCCATAAGAAACAAGACCTCC-3,  
CPTIB  reverse, 5- CAGAAAGTACCTCAGCCAGGAAAG-3,  
MCAD forward, 5-GTTGAACTCGCTAGGCTCAGTTAC-3, 
MCAD reverse, 5-CTCTGTGTTGAATCCATAGCCTCC-3, 
PDK4 forward, 5-AGGGAGGTCGAGCTGTTCTC-3,  
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PDK4 reverse, 5- GGAGTGTTCACTAAGCGGTCA-3,  
PPARalpha forward, 5’-ACAAGGCCTCAGGGTACCA-3, 
PPARalpha reverse, 5’-GCCGAAAGAAGCCCTTACAG-3, 
PGC1alpha forward, 5’-CAGCCTCTTTGCCCAGATCT-3 
PGC1alpha reverse, 5’-CCGCTAGCAAGTTTGCCTCA-3 
18S rRNA forward, 5-GCAATTATTCCCCATGAACG-3, 
18s rRNA reverse, 5’-GGCCTCACTAAACCATCCAA -3, 
 
Statistics- Statistical analyses were performed using Student’s 2 tailed t-test.  























Figure 3-1.  Tissue specific chemically inducible Malonyl-CoA Decarboxylase. (A)   
Schematic diagram of MCD transgene. (B) Tg-fMCD
skel
 mice were injected i.p. with 
vehicle or Shield-1 at various doses. Samples were collected 24 hours after injection and 
muscle samples were blotted with the indicated antibodies. (C) Dose and delivery vehicle 
analysis of Shield-1 in Tg-fMCD
skel
 mice. Gastrocenemius muscles from i.p. injected 
mice with vehicle or Shield-1 at varying doses and delivery methods were collected 24 





















Figure 3-2. The Development of Diet Induced Obesity and Insulin Resistance in Tg-
fMCD
skel
 mice. (A) Timeline of model for Control and Tg-fMCD
skel
  mice placed on low 
fat diet (LFD) or high fat diet (HFD) followed by treatment of Shield-1 to induce 
MLYCD within the skeletal muscle. (B) Mice were weighed weekly to monitor body 
weight gain. (C) Confirmation of glucose intolerance by glucose tolerance test (GTT) and 
(D) insulin in control and Tg-fMCD
skel
 mice. (E) Insulin tolerance test (ITT) confirms 











Figure 3-3. Acute Induction of MCD Does Not Reverse Diet Induced Obesity  
or Insulin Resistance.  Tg-fMCD
skel
 and control mice on HFD and LFD received 8  
doses of Shield-1 (60 mg/kg) or vehicle control. (A) Body weights were measured  
before and after Shield-1 treatment. (B) Mice were subjected to a GTT to  










































Figure 3-4. MCD induction suppresses AKT signaling and fatty acid oxidation. 
Western blot of gastrocenemius muscle isolated from Tg-fMCD
skel
 and control mice on 
LFD or HFD given Shield-1 (60mg/kg) or vehicle for 5 days. Mice were fasted for 6 
hours before an insulin stimulation. (A) AKT Ser 473 phosphorylation, and ACC 
phosphorylation at Ser79 are normalized to total protein and quantified. CPT1B and 
OXPHOS complexes are normalized to alpha Tubulin and quantified. Samples were 
blotted with FKBP12 (for transgene stabilization), MLYCD (endogenous expression), 
mCherry (transgene expression) and alpha Tubulin (loading control). (B) AMPK Thr 172 
phophorylation was determined, normalized for total AMPK and quantified. (C) 
Endogenous levels of MLYCD were determined, normalized to alpha Tubulin, and 
quantified. Results are expressed as *p< 0.05 compared to WT HFD Shield. Data 




Figure 3-5. MCD transgene expression and Shield-1 stabilization is specific to 
skeletal muscle. Western blot of liver (A) pancreas (B) and heart (C) tissue extracted 
from Tg-fMCD
skel 
 and control mice on HFD and LFD treated with Shield-1 (5 doses at 
60 mg/kg) or vehicle. Samples were blotted for FKBP12 (for transgene stabilization), 
MLYCD (endogenous expression), mCherry (transgene expression), alpha Tubulin 
(loading control). Positive controls for mCherry and FKBP are derived from skeletal 
muscle of Tg-fMCD
skel









































Figure 3-6. Fatty Acid Oxidation genes are down-regulated upon induction of MCD.  
qPCR analysis of key fatty acid oxidation genes, CPT1B, MCAD, ACOT1, PDK4 and 
transcriptional regulators of lipid oxidation, PPARα PGC1α.  * p< 0.05 compared to WT 
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OVERVIEW OF RESEARCH FINDINGS 
 In this thesis, a simple and broadly applicable method for regulating protein and 
pathway function in vivo has been developed. This method combines mouse conditional 
transgenics and synthetic posttranslational protein stabilization to produce mice that have 
dually regulated enzyme expression.  The conditional KO of genes in mice has lead to a 
revolution in the understanding of gene function in vivo. Small molecule inhibition of 
specific proteins would be better for understanding protein function in adult animals.  
However, some proteins have no such inhibitors and mostly all small molecule inhibitors 
have off target effects that cannot be controlled for without an existing KO mouse to test 
the compounds against. Allele-specific small molecules can be made to selectively and 
potently alter protein function by allowing the WT allele to be used in control 
experiments for specificity. The targeted chemical-genetic method developed in this 
thesis allows the study of unknown genes, enzymes where the reaction mechanism is not 
known, structurally similar protein families or proteins where small molecule inhibitors 
are in demand, but not available. Therefore, new methodology is needed and important 
for deconstructing metabolic pathways that are highly interdependent and cross-
regulated. Our method provides a practical, specific, and reversible means of 
manipulating metabolic pathways in adult mice to provide biological insight. 
 In order to produce dose dependent, small molecule-regulated posttranslational 
stabilization to study metabolites in vivo, we used a synthetic posttranslational protein 
stabilization system developed by Tom Wandless’ lab. Wandless constructed a modified 
FK506 binding protein 12 (FKBP12) that binds to and is reversibly stabilized by a 
synthetic, biologically inert small molecule, Shield-1. Several features were added to the 
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FKBP12/Shield-1 system to create internal controls for transgene insertion, 
recombination, and stabilization. A picornavirus 2A peptide-linked mCherry was fused 
in-frame to enable a ratiometric, autonomous measurement of stabilization.  The 
conditional protein stabilization domain (FKBP12) was placed after a floxed stop cassette 
to enable Cre recombinase mediated targeting of the regulated domain. Heterospecific lox 
sites to minimize cross-genomic recombination with loxp sites were used. All of the 
activities are linked to a specific fluorophore to enable direct visualization of transgene 
expression, CRE-mediated recombination and Shield-1 induced stabilization. This vector 
was used to regulate MCD protein and enzyme activity. MCD is an ideal candidate for 
posttranslational protein regulation because of its enzymatic regulation of its substrate, 
malonyl-CoA. Exerting control over malonyl-CoA through MCD has broad experimental 
utility because malonyl-CoA is situated at a critical node in fatty acid metabolism. 
Malonyl-CoA is the product of the rate- limiting step in de novo fatty acid synthesis and 
elongation, and allosterically inhibits the rate-setting step in fatty acid beta-oxidation. 
Regulation of malonyl-CoA by MCD has been shown to play a role in neurochemistry, 
cancer metabolism, obesity and diabetes.  
  Small molecule regulation of MCD was validated by several methods. Two HEK 
293T stable cell lines were produced that expressed FKBP12-eYFP-MLYCD-2A-
mCherry (FY-MLYCD) or FKBP12-eYFP-2A-mCherry (FYFP). These stables cell lines 
were used to characterize the system initially. Addition of Shield-1 induced FYFP and 
FY-MLYCD in a dose-dependent and reversible manner. Saturation of stability was 
achieved 12 hours post treatment and stable cells returned to basal levels 48 hours after 
Shield-1 removal. To demonstrate that the FY-MLYCD fusion retained enzymatic 
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activity, Shield-1 or vehicle was added to FY-MLYCD stable cells for 16 hours and then 
assayed for MCD activity. Shield-1 induced a 4-fold increase in MLYCD activity. These 
experiments show Shield-1 can regulate MCD protein levels and enzyme activity. The 
vector was modified to affect metabolism in live behaving mice.  First, a lox2272 flanked 
eCFP cassette was cloned into a ubiquitous mammalian expression vector and the FY-
MLYCD transgene was cloned downstream of the floxed stop cassette. This feature 
allowed FY-MLYCD to be produced only after CRE-mediated excisions of the eCFP 
stop cassette. Transgenic mice expressing Lox2272-eCFPcaax pA Lox2272-FKBP12-
eYFP-MLYCD-2a-mCherry (Tg-fMCD) were produced and characterized for eCFP 
expression by Western blot and direct epifluorescent visualization in cryosections. CFP 
expression was the highest in the muscle, pancreas, and kidney, but not in the brain and 
liver. These mice were then crossed to mice that ubiquitously express a tamoxifen-
inducible Cre recombinase, CRE
ERT2





 animals were injected i.p with tamoxifen to induce 
recombination of the eCFPcaax domain in vivo. Shield-1 was administered to induce 
transgene expression of FY-MLYCD. Recombination was seen in vivo as the expression 
of untargeted mCherry, and stabilization was visualized by the expression of cytoplasmic 
eYFP. Shield-1 stabilized FY-MLYCD in tissues that express the transgene, including the 
pancreas, skeletal muscle, heart, and adipose tissue. Tamoxifine treated Tg-fMCD
ERT2
 
mice were given Shield-1 or vehicle and assayed for their ability to fully oxidize 
radiolabeled palmitate to CO2. Shield-1 induced an ∼3-fold increase in fatty acid 
oxidation, during the fed state, in Shield-1 treated Tg-fMCD
ERT2 
mice, but not vehicle 
control treated Tg-fMCD
ERT2 
mice. The system was tested in a tissue specific context by 
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crossing transgenic mice  (Tg-fMCD) to mice expressing Cre recombinase from human 
alpha-skeletal muscle actin promoter to produce Tg-fMCD
skel 
mice.  Administration of 
Shield-1 to Tg-fMCD
skel 
mice resulted in the induction of eYFP-MLYCD with increasing 
doses of Shield-1. These experiments show the utility of regulating MCD through a 
targeted chemical-genetic technique that allows rapid and reversible regulation of MCD 
protein and enzymatic activity in a tissue-specific and temporal manner to affect 
metabolic pathways. 
 In addition to demonstrating the power of targeted chemical-genetics in 
generating mice with dually regulated enzyme expression, I have used this approach to 
decipher the role of MCD in diet induced insulin resistance in the skeletal muscle. 
Investigative support for increasing lipid oxidation as a means to remove excess lipid 
deposition in the muscle, increase glucose sensitivity, and restore mitochondrial function 
has been a sought after method to improve metabolic health in diabetic patients. Studies 
using transgenic mouse models of tissue-targeted deletions or overexpression of genes 
involved in fatty acid metabolism have arrived to different conclusions on the benefits of 
increased fatty acid uptake in the skeletal muscle. In this thesis, it is established that acute 
overexpression of MCD in a model of skeletal muscle insulin resistance increases the 
severity of diet induced glucose intolerance. The evidence shows that acute 
overexpression of MCD by Shield-1 treatment did not improve insulin sensitivity as 
measured by GTT and decreased phosphorylation of AKT Ser
473
 in obese insulin resistant 
Tg-fMCDSkel mice. Acute MCD overexpression by Shield-1 treatment did not change body 
weights of obese insulin resistant Tg-fMCDSkel mice compared to their wiltype controls. 
Acute overexpression of MCD by Shield-1 treatment decreased protein abundance of 
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CPT1B, MCD, and components of oxidative phosphorylation complexes 2, 3, 4 in obese 
insulin resistant Tg-fMCDSkel mice. The decrease in protein expression was due to 
transcriptional down-regulation of oxidative genes in a PPARα dependent manner. 
Combined, these results indicate that excessive MCD overexpression contributes to 
sustained metabolic dysfunction in obesity induced insulin resistance in the skeletal 
muscle. 
 
DIRECTIONS FOR FUTURE RESEARCH 
Would an exercise intervention improve skeletal muscle insulin resistance with 
Shield-1 mediated MCD overexpression? 
 The effects of increased fatty acid oxidation through MCD overexpression in our 
model proved more detrimental than beneficial. It is important to note that our transgenic 
mice continued to consume the high fat diet during the Shield-1 treatment periods with no 
opportunity to increase energy expenditure through exercise.  It is unclear if an 
intervention of Shield-1 treatment to stimulate MCD overexpression in combination with 
treadmill exercise would stimulate a positive health outcome through weight loss and 
increased glucose sensitivity in Tg-fMCD
skel 
mice.  By housing transgenic mice and their 
controls in an Oxymax/CLAMS (comprehensive laboratory animal monitoring system) 
with a treadmill, we can determine their food intake, body mass, activity levels, and use 
indirect calorimetry to determine their whole body substrate oxidation levels to assess 
changes in their diabetic phenotype after the exercise regime. To assess insulin 
sensitivity, glucose tolerance tests administered before and after exercise training are 
used to characterize improvements in glucose intolerance. To determine improvements in 
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insulin sensitivity from exercise, we would measure mRNA levels of PPARα and PGC1α 
in red (oxidative) and white (glycolytic) skeletal muscles. In the skeletal muscle, PGC1α 
has been shown to stimulate mitochondrial biogenesis and regulate genes involved in 
fatty acid catabolism through its coactivation with the PPARs and estrogen-related 
receptor α (ERRα). PGC1α is decreased by inactivity and chronic high fat feeding and 
increased in response to acute exercise (126, 133). PGC1α mediated remodeling of 
downstream metabolic pathways, such as the TCA cycle and electron transport chain will 
also be evaluated because human and animal studies link decreased PGC1α activity and 
the reduction of genes involved in oxidative phosphorylation to the development of type 
2 diabetes (119, 133, 134). I predict exercise training will enhance the muscle’s capacity 
to tolerate high levels of fatty acids through PPARα and PGC1α activation and increase 
insulin sensitivity. 
Would a time course and dose treatment of Shield-1 alter insulin resistance in 
obesity induced insulin resistant Tg-fMCD
skel
? 
 An observation presented in this thesis is that high fat diet induced insulin 
resistance is associated with decreased muscle fatty acid oxidation, transcriptional 
downregulation of PPARα and PGC1α, and reduced protein abundance of electron 
transport complexes. To better assess if MCD expression increases the severity of insulin 
resistance and PPARα repression, a time course and dose dependence of Shield-1 
treatment should be performed. I predict a lower dose of Shield-1 will produce a milder 
form of insulin resistance during an acute (5 day), 2 week, or 1month extended Shield-1 
treatment in Tg-fMCD
skel 
mice compared to wildtype obese controls. Tg-fMCD
skel  
mice  
treated with an extended time course of Shield-1 at 60mg/kg will remain diabetic with 
 80 
transcriptional repression of PPARα and PGC1α and decreased expression of lipid 
oxidation genes.   
 
Does MCD expression generate a ligand that negatively regulates the transcriptional 
activation of oxidative genes by PPARα in the skeletal muscle?    
 The PPARs belong to a family of nuclear hormone receptors that are activated by 
a variety of lipid-derived ligands. To this date, their natural ligands still remain a 
mystery. There are still many unanswered questions, including their identities, i.e., what 
are the concentrations required in the nucleus to trigger a PPAR-dependent 
transcriptional response? Are there several ligands working together to mediate this 
response? It would be important to identify the ligand that allows PPARα to respond to 
dietary stimuli to maintain energy homeostasis as the identification of PPAR ligands have 
important clinical implications in treating metabolic disease. To identify the potential 
ligand(s), a metabolomics approach using isolated muscle nuclear fractions from 
transgenic and control mice treated with Shield-1 or vehicle are compared. The data 
generated will be critical for understanding the function of PPARα and their use as 
potential drug targets in metabolic disease, such as diabetes. I predict pathways involved 
in neutral lipid synthesis are up regulated in response to increased fatty acid oxidation as 
a negative feedback mechanism to decrease oxidative gene expression as a protective 





Public Health Significance 
 Skeletal muscle plays an important role in maintaining insulin mediated glucose 
sensitivity and regulating fatty acid metabolism. Studies of obese, insulin resistant 
individual and diabetics have implicated dyslipidemia and intramuscular accumulation of 
fatty acid metabolites as core features for the development of these disease states. 
Understanding the mechanisms that the muscle uses to handle excess lipid intake, will 
further enhance our understanding to develop new treatments of obesity related diseases.  
Enhancing fatty acid oxidation has been proposed as a therapeutic measure to prevent the 
accumulation of lipotoxic intermediates that are deemed deleterious by acting on and 
inhibiting key regulators of the insulin-signaling pathway. MCD is a key enzyme 
responsible for regulating malonyl-CoA concentration and functions in the control of 
balancing lipid oxidation and glucose metabolism in the muscle.  A whole body knock 
out of MCD protected against the development of diet induced insulin resistance, but the 
tissue specific mechanisms remain unresolved since MCD is expressed in multiple tissues 
that are responsible for maintaining blood glucose and energy homeostasis. Taking a 
chemical genetic approach to determine the role of skeletal muscle MCD and the 
subsequent preference for lipid oxidative pathways in a model of diet induced obesity and 
insulin resistance has demonstrated that, on the contrary, lipid oxidation foments the 
diabetic environment. The data presented in this dissertation provides novel evidence for 
the additional repression on insulin signaling and the transcriptional deactivation of 
PPARα to suppress the activation of oxidative genes through an unknown ligand 
functioning in a feed forward mechanism. Thus, therapeutic approaches aimed to 
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stimulate fatty acid oxidation will hinder the progress in finding novel treatments for 
























1. Friedman, J.M., and Halaas, J.L. 1998. Leptin and the regulation of body weight 
in mammals. Nature 395:763-770. 
2. Garrison, R.J., Higgins, M.W., and Kannel, W.B. 1996. Obesity and coronary 
heart disease. Curr Opin Lipidol 7:199-202. 
3. Friedrich, M.J. 2002. Epidemic of obesity expands its spread to developing 
countries. JAMA 287:1382-1386. 
4. Turk, M.W., Yang, K., Hravnak, M., Sereika, S.M., Ewing, L.J., and Burke, L.E. 
2009. Randomized clinical trials of weight loss maintenance: a review. J 
Cardiovasc Nurs 24:58-80. 
5. Cummings, D.E., and Schwartz, M.W. 2003. Genetics and pathophysiology of 
human obesity. Annu Rev Med 54:453-471. 
6. Schwartz, M.W., Woods, S.C., Porte, D., Jr., Seeley, R.J., and Baskin, D.G. 2000. 
Central nervous system control of food intake. Nature 404:661-671. 
7. Dowell, P., Hu, Z., and Lane, M.D. 2005. Monitoring energy balance: metabolites 
of fatty acid synthesis as hypothalamic sensors. Annu Rev Biochem 74:515-534. 
8. Wolfgang, M.J., and Lane, M.D. 2006. The role of hypothalamic malonyl-CoA in 
energy homeostasis. J Biol Chem 281:37265-37269. 
9. Gao, Q., and Horvath, T.L. 2007. Neurobiology of feeding and energy 
expenditure. Annu Rev Neurosci 30:367-398. 
10. Hamilton, M.T., Hamilton, D.G., and Zderic, T.W. 2007. Role of low energy 
expenditure and sitting in obesity, metabolic syndrome, type 2 diabetes, and 
cardiovascular disease. Diabetes 56:2655-2667. 
 84 
11. Stumvoll, M., Goldstein, B.J., and van Haeften, T.W. 2005. Type 2 diabetes: 
principles of pathogenesis and therapy. The Lancet 365:1333-1346. 
12. Morino, K., Petersen, K.F., and Shulman, G.I. 2006. Molecular Mechanisms of 
Insulin Resistance in Humans and Their Potential Links With Mitochondrial 
Dysfunction. Diabetes 55:S9-S15. 
13. Loos, R.J., and Bouchard, C. 2003. Obesity--is it a genetic disorder? J Intern Med 
254:401-425. 
14. Wild, S., Roglic, G., Green, A., Sicree, R., and King, H. 2004. Global prevalence 
of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 
27:1047-1053. 
15. Lumeng, C.N., and Saltiel, A.R. 2011. Inflammatory links between obesity and 
metabolic disease. J Clin Invest 121:2111-2117. 
16. Muoio, D.M., and Neufer, P.D. 2012. Lipid-induced mitochondrial stress and 
insulin action in muscle. Cell Metab 15:595-605. 
17. Muoio, D.M., and Newgard, C.B. 2008. Fatty acid oxidation and insulin action: 
when less is more. Diabetes 57:1455-1456. 
18. Taniguchi, C.M., Emanuelli, B., and Kahn, C.R. 2006. Critical nodes in signalling 
pathways: insights into insulin action. Nat Rev Mol Cell Biol 7:85-96. 
19. Sano, H., Eguez, L., Teruel, M.N., Fukuda, M., Chuang, T.D., Chavez, J.A., 
Lienhard, G.E., and McGraw, T.E. 2007. Rab10, a target of the AS160 Rab GAP, 
is required for insulin-stimulated translocation of GLUT4 to the adipocyte plasma 
membrane. Cell Metab 5:293-303. 
 85 
20. McGarry, J.D., and Foster, D.W. 1980. Regulation of hepatic fatty acid oxidation 
and ketone body production. Annu Rev Biochem 49:395-420. 
21. Lopaschuk, G.D., Belke, D.D., Gamble, J., Itoi, T., and Schonekess, B.O. 1994. 
Regulation of fatty acid oxidation in the mammalian heart in health and disease. 
Biochim Biophys Acta 1213:263-276. 
22. Bartlett, K. 1993. Methods for the investigation of hypoglycaemia with particular 
reference to inherited disorders of mitochondrial beta-oxidation. Baillieres Clin 
Endocrinol Metab 7:643-667. 
23. Gillingham, M.B., Harding, C.O., Schoeller, D.A., Matern, D., and Purnell, J.Q. 
2013. Altered body composition and energy expenditure but normal glucose 
tolerance among humans with a long-chain fatty acid oxidation disorder. Am J 
Physiol Endocrinol Metab 305:E1299-1308. 
24. Lin, J., Handschin, C., and Spiegelman, B.M. 2005. Metabolic control through the 
PGC-1 family of transcription coactivators. Cell Metab 1:361-370. 
25. Witkowski, A., Thweatt, J., and Smith, S. 2011. Mammalian ACSF3 protein is a 
malonyl-CoA synthetase that supplies the chain extender units for mitochondrial 
fatty acid synthesis. J Biol Chem 286:33729-33736. 
26. Sloan, J.L., Johnston, J.J., Manoli, I., Chandler, R.J., Krause, C., Carrillo-
Carrasco, N., Chandrasekaran, S.D., Sysol, J.R., O'Brien, K., Hauser, N.S., et al. 
2011. Exome sequencing identifies ACSF3 as a cause of combined malonic and 
methylmalonic aciduria. Nat Genet 43:883-886. 
27. Alfares, A., Nunez, L.D., Al-Thihli, K., Mitchell, J., Melancon, S., Anastasio, N., 
Ha, K.C., Majewski, J., Rosenblatt, D.S., and Braverman, N. 2011. Combined 
 86 
malonic and methylmalonic aciduria: exome sequencing reveals mutations in the 
ACSF3 gene in patients with a non-classic phenotype. J Med Genet 48:602-605. 
28. Melo, D.R., Kowaltowski, A.J., Wajner, M., and Castilho, R.F. 2011. 
Mitochondrial energy metabolism in neurodegeneration associated with 
methylmalonic acidemia. J Bioenerg Biomembr 43:39-46. 
29. Hiltunen, J.K., Schonauer, M.S., Autio, K.J., Mittelmeier, T.M., Kastaniotis, A.J., 
and Dieckmann, C.L. 2009. Mitochondrial fatty acid synthesis type II: more than 
just fatty acids. J Biol Chem 284:9011-9015. 
30. Thampy, K.G., and Wakil, S.J. 1988. Regulation of acetyl-coenzyme A 
carboxylase. I. Purification and properties of two forms of acetyl-coenzyme A 
carboxylase from rat liver. J Biol Chem 263:6447-6453. 
31. Wakil, S.J., Stoops, J.K., and Joshi, V.C. 1983. Fatty acid synthesis and its 
regulation. Annu Rev Biochem 52:537-579. 
32. Abu-Elheiga, L., Almarza-Ortega, D.B., Baldini, A., and Wakil, S.J. 1997. 
Human acetyl-CoA carboxylase 2. Molecular cloning, characterization, 
chromosomal mapping, and evidence for two isoforms. J Biol Chem 272:10669-
10677. 
33. Abu-Elheiga, L., Brinkley, W.R., Zhong, L., Chirala, S.S., Woldegiorgis, G., and 
Wakil, S.J. 2000. The subcellular localization of acetyl-CoA carboxylase 2. Proc 
Natl Acad Sci U S A 97:1444-1449. 
34. Rubink, D.S., and Winder, W.W. 2005. Effect of phosphorylation by AMP-
activated protein kinase on palmitoyl-CoA inhibition of skeletal muscle acetyl-
CoA carboxylase. J Appl Physiol (1985) 98:1221-1227. 
 87 
35. Winder, W.W., and Hardie, D.G. 1996. Inactivation of acetyl-CoA carboxylase 
and activation of AMP-activated protein kinase in muscle during exercise. Am J 
Physiol 270:E299-304. 
36. Sacksteder, K.A., Morrell, J.C., Wanders, R.J., Matalon, R., and Gould, S.J. 1999. 
MCD encodes peroxisomal and cytoplasmic forms of malonyl-CoA 
decarboxylase and is mutated in malonyl-CoA decarboxylase deficiency. J Biol 
Chem 274:24461-24468. 
37. Yano, S., Sweetman, L., Thorburn, D.R., Mofidi, S., and Williams, J.C. 1997. A 
new case of malonyl coenzyme A decarboxylase deficiency presenting with 
cardiomyopathy. European Journal of Pediatrics 156:382-383. 
38. Brown, G.K., Scholem, R.D., Bankier, A., and Danks, D.M. 1984. Malonyl 
coenzyme a decarboxylase deficiency. Journal of Inherited Metabolic Disease 
7:21-26. 
39. MacPhee, G.B., Logan, R.W., Mitchell, J.S., Howells, D.W., Tsotsis, E., and 
Thorburn, D.R. 1993. Malonyl coenzyme A decarboxylase deficiency. Archives of 
Disease in Childhood 69:433-436. 
40. Matalon, R., Michaels, K., Kaul, R., Whitman, V., Rodriguez-Novo, J., Goodman, 
S., and Thorburn, D. 1993. Malonic aciduria and cardiomyopathy. Journal of 
Inherited Metabolic Disease 16:571-573. 
41. Ussher, J.R., and Lopaschuk, G.D. 2009. Targeting malonyl CoA inhibition of 
mitochondrial fatty acid uptake as an approach to treat cardiac 
ischemia/reperfusion. Basic Res Cardiol 104:203-210. 
 88 
42. Zhou, W., Tu, Y., Simpson, P.J., and Kuhajda, F.P. 2009. Malonyl-CoA 
decarboxylase inhibition is selectively cytotoxic to human breast cancer cells. 
Oncogene 28:2979-2987. 
43. McGarry, J.D., and Brown, N.F. 1997. The mitochondrial carnitine 
palmitoyltransferase system. From concept to molecular analysis. Eur J Biochem 
244:1-14. 
44. Wolfgang, M.J., Kurama, T., Dai, Y., Suwa, A., Asaumi, M., Matsumoto, S., Cha, 
S.H., Shimokawa, T., and Lane, M.D. 2006. The brain-specific carnitine 
palmitoyltransferase-1c regulates energy homeostasis. Proc Natl Acad Sci U S A 
103:7282-7287. 
45. Lee, J., and Wolfgang, M.J. 2012. Metabolomic profiling reveals a role for CPT1c 
in neuronal oxidative metabolism. BMC Biochem 13:23. 
46. Zammit, V.A. 2008. Carnitine palmitoyltransferase 1: central to cell function. 
IUBMB Life 60:347-354. 
47. Lopez-Vinas, E., Bentebibel, A., Gurunathan, C., Morillas, M., de Arriaga, D., 
Serra, D., Asins, G., Hegardt, F.G., and Gomez-Puertas, P. 2007. Definition by 
functional and structural analysis of two malonyl-CoA sites in carnitine 
palmitoyltransferase 1A. J Biol Chem 282:18212-18224. 
48. Randle, P.J., Garland, P.B., Hales, C.N., and Newsholme, E.A. 1963. The glucose 
fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of 
diabetes mellitus. Lancet 1:785-789. 
49. Randle, P.J. 1998. Regulatory interactions between lipids and carbohydrates: the 
glucose fatty acid cycle after 35 years. Diabetes Metab Rev 14:263-283. 
 89 
50. Hue, L., and Taegtmeyer, H. 2009. The Randle cycle revisited: a new head for an 
old hat. Am J Physiol Endocrinol Metab 297:E578-591. 
51. Banaszynski, L.A., Chen, L.C., Maynard-Smith, L.A., Ooi, A.G., and Wandless, 
T.J. 2006. A rapid, reversible, and tunable method to regulate protein function in 
living cells using synthetic small molecules. Cell 126:995-1004. 
52. Banaszynski, L.A., Sellmyer, M.A., Contag, C.H., Wandless, T.J., and Thorne, 
S.H. 2008. Chemical control of protein stability and function in living mice. Nat 
Med 14:1123-1127. 
53. Schoeber, J.P., van de Graaf, S.F., Lee, K.P., Wittgen, H.G., Hoenderop, J.G., and 
Bindels, R.J. 2009. Conditional fast expression and function of multimeric 
TRPV5 channels using Shield-1. Am J Physiol Renal Physiol 296:F204-211. 
54. Glass, M., Busche, A., Wagner, K., Messerle, M., and Borst, E.M. 2009. 
Conditional and reversible disruption of essential herpesvirus proteins. Nat 
Methods 6:577-579. 
55. Rodriguez, S., and Wolfgang, M.J. 2012. Targeted chemical-genetic regulation of 
protein stability in vivo. Chem Biol 19:391-398. 
56. Bishop, A.C., Ubersax, J.A., Petsch, D.T., Matheos, D.P., Gray, N.S., Blethrow, 
J., Shimizu, E., Tsien, J.Z., Schultz, P.G., Rose, M.D., et al. 2000. A chemical 
switch for inhibitor-sensitive alleles of any protein kinase. Nature 407:395-401. 
57. Haruki, H., Nishikawa, J., and Laemmli, U.K. 2008. The anchor-away technique: 
rapid, conditional establishment of yeast mutant phenotypes. Mol Cell 31:925-
932. 
 90 
58. Matsuzawa, S., Cuddy, M., Fukushima, T., and Reed, J.C. 2005. Method for 
targeting protein destruction by using a ubiquitin-independent, proteasome-
mediated degradation pathway. Proc Natl Acad Sci U S A 102:14982-14987. 
59. McGinness, K.E., Baker, T.A., and Sauer, R.T. 2006. Engineering controllable 
protein degradation. Mol Cell 22:701-707. 
60. Robinson, M.S., Sahlender, D.A., and Foster, S.D. 2010. Rapid inactivation of 
proteins by rapamycin-induced rerouting to mitochondria. Dev Cell 18:324-331. 
61. Chen, X., Ye, H., Kuruvilla, R., Ramanan, N., Scangos, K.W., Zhang, C., 
Johnson, N.M., England, P.M., Shokat, K.M., and Ginty, D.D. 2005. A chemical-
genetic approach to studying neurotrophin signaling. Neuron 46:13-21. 
62. Karpova, A.Y., Tervo, D.G., Gray, N.W., and Svoboda, K. 2005. Rapid and 
reversible chemical inactivation of synaptic transmission in genetically targeted 
neurons. Neuron 48:727-735. 
63. Liu, K.J., Arron, J.R., Stankunas, K., Crabtree, G.R., and Longaker, M.T. 2007. 
Chemical rescue of cleft palate and midline defects in conditional GSK-3beta 
mice. Nature 446:79-82. 
64. Stankunas, K., Bayle, J.H., Gestwicki, J.E., Lin, Y.M., Wandless, T.J., and 
Crabtree, G.R. 2003. Conditional protein alleles using knockin mice and a 
chemical inducer of dimerization. Mol Cell 12:1615-1624. 
65. Bonger, K.M., Chen, L.C., Liu, C.W., and Wandless, T.J. 2011. Small-molecule 
displacement of a cryptic degron causes conditional protein degradation. Nat 
Chem Biol 7:531-537. 
 91 
66. Iwamoto, M., Bjorklund, T., Lundberg, C., Kirik, D., and Wandless, T.J. 2010. A 
general chemical method to regulate protein stability in the mammalian central 
nervous system. Chem Biol 17:981-988. 
67. Kanke, M., Nishimura, K., Kanemaki, M., Kakimoto, T., Takahashi, T.S., 
Nakagawa, T., and Masukata, H. 2011. Auxin-inducible protein depletion system 
in fission yeast. BMC Cell Biol 12:8. 
68. Nishimura, K., Fukagawa, T., Takisawa, H., Kakimoto, T., and Kanemaki, M. 
2009. An auxin-based degron system for the rapid depletion of proteins in 
nonplant cells. Nat Methods 6:917-922. 
69. Janse, D.M., Crosas, B., Finley, D., and Church, G.M. 2004. Localization to the 
proteasome is sufficient for degradation. J Biol Chem 279:21415-21420. 
70. Maynard-Smith, L.A., Chen, L.C., Banaszynski, L.A., Ooi, A.G., and Wandless, 
T.J. 2007. A directed approach for engineering conditional protein stability using 
biologically silent small molecules. J Biol Chem 282:24866-24872. 
71. Provost, E., Rhee, J., and Leach, S.D. 2007. Viral 2A peptides allow expression of 
multiple proteins from a single ORF in transgenic zebrafish embryos. Genesis 
45:625-629. 
72. Szymczak, A.L., Workman, C.J., Wang, Y., Vignali, K.M., Dilioglou, S., Vanin, 
E.F., and Vignali, D.A. 2004. Correction of multi-gene deficiency in vivo using a 
single 'self-cleaving' 2A peptide-based retroviral vector. Nat Biotechnol 22:589-
594. 
73. An, J., Muoio, D.M., Shiota, M., Fujimoto, Y., Cline, G.W., Shulman, G.I., 
Koves, T.R., Stevens, R., Millington, D., and Newgard, C.B. 2004. Hepatic 
 92 
expression of malonyl-CoA decarboxylase reverses muscle, liver and whole-
animal insulin resistance. Nat Med 10:268-274. 
74. Yang, W., Rozamus, L.W., Narula, S., Rollins, C.T., Yuan, R., Andrade, L.J., 
Ram, M.K., Phillips, T.B., van Schravendijk, M.R., Dalgarno, D., et al. 2000. 
Investigating protein-ligand interactions with a mutant FKBP possessing a 
designed specificity pocket. J Med Chem 43:1135-1142. 
75. Reamy, A.A., and Wolfgang, M.J. 2011. Carnitine palmitoyltransferase-1c gain-
of-function in the brain results in postnatal microencephaly. J Neurochem 
118:388-398. 
76. Araki, K., Araki, M., and Yamamura, K. 2002. Site-directed integration of the cre 
gene mediated by Cre recombinase using a combination of mutant lox sites. 
Nucleic Acids Res 30:e103. 
77. Ruzankina, Y., Pinzon-Guzman, C., Asare, A., Ong, T., Pontano, L., Cotsarelis, 
G., Zediak, V.P., Velez, M., Bhandoola, A., and Brown, E.J. 2007. Deletion of the 
developmentally essential gene ATR in adult mice leads to age-related 
phenotypes and stem cell loss. Cell Stem Cell 1:113-126. 
78. Miniou, P., Tiziano, D., Frugier, T., Roblot, N., Le Meur, M., and Melki, J. 1999. 
Gene targeting restricted to mouse striated muscle lineage. Nucleic Acids Res 
27:e27-e30. 
79. Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., 
and Handa, H. 2010. Identification of a primary target of thalidomide 
teratogenicity. Science 327:1345-1350. 
 93 
80. Rossi, F.M., and Blau, H.M. 1998. Recent advances in inducible gene expression 
systems. Curr Opin Biotechnol 9:451-456. 
81. Abu-Elheiga, L., Matzuk, M.M., Abo-Hashema, K.A., and Wakil, S.J. 2001. 
Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-
CoA carboxylase 2. Science 291:2613-2616. 
82. Harada, N., Oda, Z., Hara, Y., Fujinami, K., Okawa, M., Ohbuchi, K., Yonemoto, 
M., Ikeda, Y., Ohwaki, K., Aragane, K., et al. 2007. Hepatic de novo lipogenesis 
is present in liver-specific ACC1-deficient mice. Mol Cell Biol 27:1881-1888. 
83. Olson, D.P., Pulinilkunnil, T., Cline, G.W., Shulman, G.I., and Lowell, B.B. 
2010. Gene knockout of Acc2 has little effect on body weight, fat mass, or food 
intake. Proc Natl Acad Sci U S A 107:7598-7603. 
84. Savage, D.B., Choi, C.S., Samuel, V.T., Liu, Z.X., Zhang, D., Wang, A., Zhang, 
X.M., Cline, G.W., Yu, X.X., Geisler, J.G., et al. 2006. Reversal of diet-induced 
hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide 
inhibitors of acetyl-CoA carboxylases 1 and 2. J Clin Invest 116:817-824. 
85. Matsuda, T., and Cepko, C.L. 2007. Controlled expression of transgenes 
introduced by in vivo electroporation. Proc Natl Acad Sci U S A 104:1027-1032. 
86. Saha, A.K., Schwarsin, A.J., Roduit, R., Masse, F., Kaushik, V., Tornheim, K., 
Prentki, M., and Ruderman, N.B. 2000. Activation of malonyl-CoA 
decarboxylase in rat skeletal muscle by contraction and the AMP-activated 
protein kinase activator 5-aminoimidazole-4-carboxamide-1-beta -D-
ribofuranoside. J Biol Chem 275:24279-24283. 
 94 
87. DeFronzo, R.A., Gunnarsson, R., Bj, xF, rkman, O., Olsson, M., and Wahren, J. 
1985. Effects of insulin on peripheral and splanchnic glucose metabolism in 
noninsulin-dependent (type II) diabetes mellitus. J Clin Invest 76:149-155. 
88. Warram, J.H., Martin, B.C., Krolewski, A.S., Soeldner, J.S., and Kahn, C.R. 
1990. Slow glucose removal rate and hyperinsulinemia precede the development 
of type II diabetes in the offspring of diabetic parents. Ann Intern Med 113:909-
915. 
89. Kelley, D.E., Williams, K.V., Price, J.C., McKolanis, T.M., Goodpaster, B.H., 
and Thaete, F.L. 2001. Plasma Fatty Acids, Adiposity, and Variance of Skeletal 
Muscle Insulin Resistance in Type 2 Diabetes Mellitus. Journal of Clinical 
Endocrinology & Metabolism 86:5412-5419. 
90. Muoio, D.M., and Newgard, C.B. 2008. Mechanisms of disease: molecular and 
metabolic mechanisms of insulin resistance and beta-cell failure in type 2 
diabetes. Nat Rev Mol Cell Biol 9:193-205. 
91. Holland, W.L., Brozinick, J.T., Wang, L.P., Hawkins, E.D., Sargent, K.M., Liu, 
Y., Narra, K., Hoehn, K.L., Knotts, T.A., Siesky, A., et al. 2007. Inhibition of 
ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-
induced insulin resistance. Cell Metab 5:167-179. 
92. Pan, D.A., Lillioja, S., Kriketos, A.D., Milner, M.R., Baur, L.A., Bogardus, C., 
Jenkins, A.B., and Storlien, L.H. 1997. Skeletal muscle triglyceride levels are 
inversely related to insulin action. Diabetes 46:983-988. 
93. Kim, J.K., Fillmore, J.J., Sunshine, M.J., Albrecht, B., Higashimori, T., Kim, 
D.W., Liu, Z.X., Soos, T.J., Cline, G.W., O'Brien, W.R., et al. 2004. PKC-theta 
 95 
knockout mice are protected from fat-induced insulin resistance. J Clin Invest 
114:823-827. 
94. Stratford, S., DeWald, D.B., and Summers, S.A. 2001. Ceramide dissociates 3'-
phosphoinositide production from pleckstrin homology domain translocation. 
Biochem J 354:359-368. 
95. Summers, S.A., Garza, L.A., Zhou, H., and Birnbaum, M.J. 1998. Regulation of 
insulin-stimulated glucose transporter GLUT4 translocation and Akt kinase 
activity by ceramide. Mol Cell Biol 18:5457-5464. 
96. Kelley, D.E., He, J., Menshikova, E.V., and Ritov, V.B. 2002. Dysfunction of 
mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 51:2944-
2950. 
97. He, J., Watkins, S., and Kelley, D.E. 2001. Skeletal muscle lipid content and 
oxidative enzyme activity in relation to muscle fiber type in type 2 diabetes and 
obesity. Diabetes 50:817-823. 
98. Petersen, K.F., Befroy, D., Dufour, S., Dziura, J., Ariyan, C., Rothman, D.L., 
DiPietro, L., Cline, G.W., and Shulman, G.I. 2003. Mitochondrial dysfunction in 
the elderly: possible role in insulin resistance. Science 300:1140-1142. 
99. Befroy, D.E., Petersen, K.F., Dufour, S., Mason, G.F., de Graaf, R.A., Rothman, 
D.L., and Shulman, G.I. 2007. Impaired Mitochondrial Substrate Oxidation in 
Muscle of Insulin-Resistant Offspring of Type 2 Diabetic Patients. Diabetes 
56:1376-1381. 
100. Noland, R.C., Hickner, R.C., Jimenez-Linan, M., Vidal-Puig, A., Zheng, D., 
Dohm, G.L., and Cortright, R.N. 2003. Acute endurance exercise increases 
 96 
skeletal muscle uncoupling protein-3 gene expression in untrained but not trained 
humans. Metabolism 52:152-158. 
101. Hulver, M.W., Berggren, J.R., Cortright, R.N., Dudek, R.W., Thompson, R.P., 
Pories, W.J., MacDonald, K.G., Cline, G.W., Shulman, G.I., Dohm, G.L., et al. 
2003. Skeletal muscle lipid metabolism with obesity. Am J Physiol Endocrinol 
Metab 284:E741-747. 
102. Kim, J.-Y., Hickner, R.C., Cortright, R.L., Dohm, G.L., and Houmard, J.A. 2000. 
Lipid oxidation is reduced in obese human skeletal muscle. American Journal of 
Physiology - Endocrinology and Metabolism 279:E1039-E1044. 
103. Pender, C., Trentadue, A.R., Pories, W.J., Dohm, G.L., Houmard, J.A., and 
Youngren, J.F. 2006. Expression of genes regulating malonyl-CoA in human 
skeletal muscle. J Cell Biochem 99:860-867. 
104. Hoehn, K.L., Turner, N., Swarbrick, M.M., Wilks, D., Preston, E., Phua, Y., 
Joshi, H., Furler, S.M., Larance, M., Hegarty, B.D., et al. 2010. Acute or chronic 
upregulation of mitochondrial fatty acid oxidation has no net effect on whole-
body energy expenditure or adiposity. Cell Metab 11:70-76. 
105. Bruce, C.R., Hoy, A.J., Turner, N., Watt, M.J., Allen, T.L., Carpenter, K., 
Cooney, G.J., Febbraio, M.A., and Kraegen, E.W. 2009. Overexpression of 
carnitine palmitoyltransferase-1 in skeletal muscle is sufficient to enhance fatty 
acid oxidation and improve high-fat diet-induced insulin resistance. Diabetes 
58:550-558. 
106. Bouzakri, K., Austin, R., Rune, A., Lassman, M.E., Garcia-Roves, P.M., Berger, 
J.P., Krook, A., Chibalin, A.V., Zhang, B.B., and Zierath, J.R. 2008. Malonyl 
 97 
CoenzymeA decarboxylase regulates lipid and glucose metabolism in human 
skeletal muscle. Diabetes 57:1508-1516. 
107. Ussher, J.R., Koves, T.R., Jaswal, J.S., Zhang, L., Ilkayeva, O., Dyck, J.R., 
Muoio, D.M., and Lopaschuk, G.D. 2009. Insulin-stimulated cardiac glucose 
oxidation is increased in high-fat diet-induced obese mice lacking malonyl CoA 
decarboxylase. Diabetes 58:1766-1775. 
108. Choi, C.S., Savage, D.B., Abu-Elheiga, L., Liu, Z.-X., Kim, S., Kulkarni, A., 
Distefano, A., Hwang, Y.-J., Reznick, R.M., Codella, R., et al. 2007. Continuous 
fat oxidation in acetyl–CoA carboxylase 2 knockout mice increases total energy 
expenditure, reduces fat mass, and improves insulin sensitivity. Proceedings of 
the National Academy of Sciences 104:16480-16485. 
109. Koves, T.R., Ussher, J.R., Noland, R.C., Slentz, D., Mosedale, M., Ilkayeva, O., 
Bain, J., Stevens, R., Dyck, J.R., Newgard, C.B., et al. 2008. Mitochondrial 
overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin 
resistance. Cell Metab 7:45-56. 
110. Brown, G.K., Scholem, R.D., Bankier, A., and Danks, D.M. 1984. Malonyl 
coenzyme A decarboxylase deficiency. Journal of Inherited Metabolic Disease 
7:21-26. 
111. Matalon, R., Michaels, K., Kaul, R., Whitman, V., Rodriguez-Novo, J., Goodman, 
S., and Thorburn, D. 1993. Malonic aciduria and cardiomyopathy. Journal of 
Inherited Metabolic Disease 16:571-573. 
 98 
112. Yano, S., Sweetman, L., Thorburn, D.R., Mofidi, S., and Williams, J.C. 1997. A 
new case of malonyl coenzyme A decarboxylase deficiency presenting with 
cardiomyopathy. European Journal of Pediatrics 156:382-383. 
113. de Wit, M.C.Y., de Coo, I.F.M., Verbeek, E., Schot, R., Schoonderwoerd, G.C., 
Duran, M., de Klerk, J.B.C., Huijmans, J.G.M., Lequin, M.H., Verheijen, F.W., et 
al. 2006. Brain abnormalities in a case of malonyl-CoA decarboxylase deficiency. 
Molecular Genetics and Metabolism 87:102-106. 
114. Salomons, G.S., Jakobs, C., Pope, L.L., Errami, A., Potter, M., Nowaczyk, M., 
Olpin, S., Manning, N., Raiman, J.A.J., Slade, T., et al. 2007. Clinical, enzymatic 
and molecular characterization of nine new patients with malonyl-coenzyme A 
decarboxylase deficiency. Journal of Inherited Metabolic Disease 30:23-28. 
115. Bruce, C.R., Hoy, A.J., Turner, N., Watt, M.J., Allen, T.L., Carpenter, K., 
Cooney, G.J., Febbraio, M.A., and Kraegen, E.W. 2009. Overexpression of 
Carnitine Palmitoyltransferase-1 in Skeletal Muscle Is Sufficient to Enhance Fatty 
Acid Oxidation and Improve High-Fat Diet–Induced Insulin Resistance. Diabetes 
58:550-558. 
116. Abu-Elheiga, L., Oh, W., Kordari, P., and Wakil, S.J. 2003. Acetyl-CoA 
carboxylase 2 mutant mice are protected against obesity and diabetes induced by 
high-fat/high-carbohydrate diets. Proceedings of the National Academy of 
Sciences 100:10207-10212. 
117. Henique, C., Mansouri, A., Fumey, G., Lenoir, V., Girard, J., Bouillaud, F., Prip-
Buus, C., and Cohen, I. 2010. Increased Mitochondrial Fatty Acid Oxidation Is 
 99 
Sufficient to Protect Skeletal Muscle Cells from Palmitate-induced Apoptosis. 
Journal of Biological Chemistry 285:36818-36827. 
118. Perdomo, G., Commerford, S.R., Richard, A.-M.T., Adams, S.H., Corkey, B.E., 
O'Doherty, R.M., and Brown, N.F. 2004. Increased β-Oxidation in Muscle Cells 
Enhances Insulin-stimulated Glucose Metabolism and Protects against Fatty Acid-
induced Insulin Resistance Despite Intramyocellular Lipid Accumulation. Journal 
of Biological Chemistry 279:27177-27186. 
119. Mootha, V.K., Lindgren, C.M., Eriksson, K.F., Subramanian, A., Sihag, S., Lehar, 
J., Puigserver, P., Carlsson, E., Ridderstrale, M., Laurila, E., et al. 2003. PGC-
1alpha-responsive genes involved in oxidative phosphorylation are coordinately 
downregulated in human diabetes. Nat Genet 34:267-273. 
120. Funai, K., Song, H., Yin, L., Lodhi, I.J., Wei, X., Yoshino, J., Coleman, T., and 
Semenkovich, C.F. 2013. Muscle lipogenesis balances insulin sensitivity and 
strength through calcium signaling. J Clin Invest 123:1229-1240. 
121. Ukropcova, B., McNeil, M., Sereda, O., de Jonge, L., Xie, H., Bray, G.A., and 
Smith, S.R. 2005. Dynamic changes in fat oxidation in human primary myocytes 
mirror metabolic characteristics of the donor. J Clin Invest 115:1934-1941. 
122. Bruce, C.R., Thrush, A.B., Mertz, V.A., Bezaire, V., Chabowski, A., 
Heigenhauser, G.J., and Dyck, D.J. 2006. Endurance training in obese humans 
improves glucose tolerance and mitochondrial fatty acid oxidation and alters 
muscle lipid content. Am J Physiol Endocrinol Metab 291:E99-E107. 
123. Foretz, M., Hebrard, S., Leclerc, J., Zarrinpashneh, E., Soty, M., Mithieux, G., 
Sakamoto, K., Andreelli, F., and Viollet, B. 2010. Metformin inhibits hepatic 
 100 
gluconeogenesis in mice independently of the LKB1/AMPK pathway via a 
decrease in hepatic energy state. J Clin Invest 120:2355-2369. 
124. El-Mir, M.-Y., Nogueira, V., Fontaine, E., Avéret, N., Rigoulet, M., and Leverve, 
X. 2000. Dimethylbiguanide Inhibits Cell Respiration via an Indirect Effect 
Targeted on the Respiratory Chain Complex I. Journal of Biological Chemistry 
275:223-228. 
125. Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., 
Ventre, J., Doebber, T., Fujii, N., et al. 2001. Role of AMP-activated protein 
kinase in mechanism of metformin action. J Clin Invest 108:1167-1174. 
126. Sparks, L.M., Xie, H., Koza, R.A., Mynatt, R., Hulver, M.W., Bray, G.A., and 
Smith, S.R. 2005. A High-Fat Diet Coordinately Downregulates Genes Required 
for Mitochondrial Oxidative Phosphorylation in Skeletal Muscle. Diabetes 
54:1926-1933. 
127. Bonnard, C., Durand, A., Peyrol, S., Chanseaume, E., Chauvin, M.-A., Morio, B., 
xE, atrice, Vidal, H., and Rieusset, J. 2008. Mitochondrial dysfunction results 
from oxidative stress in the skeletal muscle of diet-induced insulin-resistant mice. 
J Clin Invest 118:789-800. 
128. Jans, A., Sparks, L.M., van Hees, A.M., Gjelstad, I.M., Tierney, A.C., Riserus, U., 
Drevon, C.A., Roche, H.M., Schrauwen, P., and Blaak, E.E. 2011. Transcriptional 
metabolic inflexibility in skeletal muscle among individuals with increasing 
insulin resistance. Obesity (Silver Spring) 19:2158-2166. 
129. Boyle, K.E., Canham, J.P., Consitt, L.A., Zheng, D., Koves, T.R., Gavin, T.P., 
Holbert, D., Neufer, P.D., Ilkayeva, O., Muoio, D.M., et al. 2011. A high-fat diet 
 101 
elicits differential responses in genes coordinating oxidative metabolism in 
skeletal muscle of lean and obese individuals. J Clin Endocrinol Metab 96:775-
781. 
130. Keung, W., Ussher, J.R., Jaswal, J.S., Raubenheimer, M., Lam, V.H.M., Wagg, 
C.S., and Lopaschuk, G.D. 2013. Inhibition of Carnitine Palmitoyltransferase-1 
Activity Alleviates Insulin Resistance in Diet-Induced Obese Mice. Diabetes 
62:711-720. 
131. Muoio, Deborah M., Noland, Robert C., Kovalik, J.-P., Seiler, Sarah E., Davies, 
Michael N., DeBalsi, Karen L., Ilkayeva, Olga R., Stevens, Robert D., Kheterpal, 
I., Zhang, J., et al. 2012. Muscle-Specific Deletion of Carnitine Acetyltransferase 
Compromises Glucose Tolerance and Metabolic Flexibility. Cell Metab 15:764-
777. 
132. Muoio, D.M., Way, J.M., Tanner, C.J., Winegar, D.A., Kliewer, S.A., Houmard, 
J.A., Kraus, W.E., and Dohm, G.L. 2002. Peroxisome Proliferator-Activated 
Receptor-α Regulates Fatty Acid Utilization in Primary Human Skeletal Muscle 
Cells. Diabetes 51:901-909. 
133. Koves, T.R., Li, P., An, J., Akimoto, T., Slentz, D., Ilkayeva, O., Dohm, G.L., 
Yan, Z., Newgard, C.B., and Muoio, D.M. 2005. Peroxisome Proliferator-
activated Receptor-γ Co-activator 1α-mediated Metabolic Remodeling of Skeletal 
Myocytes Mimics Exercise Training and Reverses Lipid-induced Mitochondrial 
Inefficiency. Journal of Biological Chemistry 280:33588-33598. 
134. Lowell, B.B., and Shulman, G.I. 2005. Mitochondrial dysfunction and type 2 
diabetes. Science 307:384-387. 
 102 
Susana Rodriguez      Curriculum Vitae 




2013     Ph.D. Candidate; Johns Hopkins University School of 
    Medicine; Baltimore, USA 
    Mentor: Michael Wolfgang, Ph.D. 
2006    Post-baccalaureate Student; Children’s Hospital Boston; 
    Boston, USA 
    Mentor: Mary Frances Lopez, Ph.D. 
2004     B.A. Chemistry, Biochemistry Option; California State 




2006-present    Ph.D. candidate, BCMB Program, Department of 
Biological 
    Chemistry, Johns Hopkins Univeristy School of Medicine, 
    Baltimore, USA, Michael J. Wolfgang Ph.D., advisor 
 
2006- 2006    Summer Research Student; Department of Endocrinology,  
    Children’s Hospital Boston, Boston, USA, Morris White  
    Ph.D., advisor 
 
2004-2006    Post-baccalaureate Student, Department of Endocrinology, 
    Children’s Hospital Boston, Boston, USA, Mary Frances 
    Lopez, Ph.D., advisor 
 
2001-2004    Undergraduate MARC USTAR Scholar, Department of 
    Endocrinology, Harbor-UCLA Medical Center, Carson,  
    USA, Amiya Sinha Hikim, Ph.D., advisor 
 
Academic and Professional Honors 
 
2012     Invited Student Keynote Speaker at the Johns Hopkins 
    Univeristy School of Medicine, Day of Science 
 
2012     Invited speaker at the Keystone Symposia on the Genetic 
    and Molecular Basis of Obesity and Body Weight 
    Regulation, Feb 3, 2012, Santa Fe, New Mexico 
 
2011     Keystone Symposia Underrepresented Minority   
    Scholarship Travel Award 
 
 103 
2006     Second place poster presentation at the Fifth Annual New 
    England Science Symposium, sponsored by the Harvard 
    Medical School and the Biomedical Science Careers 
    Program 
 
2005     FASEB MARC Travel Grant Award 
 
2004     Western Student Medical Research Forum Endocrinology 
    Subspecialty Award 
 
2004     Sigma XI Outstanding Undergraduate Research Award 
 
2004     First place oral presentation at the 18th Annual 
    Undergraduate Research Symposium, Graduate School of 
    Biomedical Sciences, University of Texas Medical Branch  
    at Galveston 
 
2003     Dr. Lois W. Chi-Emeritus Faculty Association Science 
    Scholarship 
 
2003     First place oral presentation in Biological Sciences at the 
    Seventeenth Annual California State University   
    Dominguez Hills Student Research Competition 
 
2002     Endocrine Society Travel Grant Award 
 
2002     NIH MARC Undergraduate Student Training in Academic 
    Research (U*STAR) Scholarship, 2002-2004 
 
2002     Sigma Xi Outstanding Undergraduate Research Award 
 





Rodriguez S, Wolfgang MJ. 2011. Targeted chemical-genetic metabolic 
regulation in vivo. Chemistry and Biology, 2012 Mar 19 (3): 391-398. 
 
Liang L, Guo WH, Esquiliano DR, Asai M, Rodriguez S, Giraud J, Kushner J, 
White MF, Lopez MF. 2009 Insulin-like Growth Factor 2 and Insulin Receptor, but 
not Insulin, Regulate Fetal Hepatic Glycogen Synthesis. Endocrinology, 2010 
Feb: 151 (2):741-7. 
 
Joshi T, Rodriguez S, Perovic V, Cockburn I, Stager S. 2009. B7-H1 Blockade 
Increases Survival of Dysfunctional CD8+ T-cell Responses and Confers 
 104 
Protection Against Leishmania donovani Infections. PLoS Pathog, 5(5): 
e1000431. 
 
Vera Y, Rodriguez S, Castanares M, Lue Y, Atienza V, Wang C, Swerdloff RS, 
Sinha Hikim AP. 2005. Functional Role of Caspases in Heat-Induced Testicular 
Germ Cell Apoptosis. Biology of Reproduction, 72: 516-22. 
 
Vera Y, Diaz-Romero M, Rodriguez S, Lue Y, Wang C, Swerdloff RS, Sinha- 
Hikim AP. 2004. Mitochondria-Dependent Pathway Is Involved in Heat-Induced 
Male Germ Cell Death: Lessons from Mutant Mice. Biology of Reproduction, 70: 
1534-40. 
 
Sinha Hikim AP, Lue Y, Yamamoto CM, Vera Y, Rodriguez S, Yen PH, Seong 
K, Wang C, Swerdloff RS. 2003. Key Apoptotic Pathways for Heat-Induced 
Programmed Germ Cell Death in the Rat Testis. Endocrinology, 144: 3167-3175. 
 
Abstracts: 
Rodriguez S, Wolfgang MJ. Targeted chemical-genetic metabolic regulation in 
vivo. Keystone Symposia on the Genetic and Molecular Basis of Obesity and 
Body Weight Regulation, Jan 29 - Feb 3, 2012, Santa Fe, New Mexico (Oral and 
poster presentation, Keystone Symposia Underrepresented Minority Scholarship 
Travel award). 
 
Rodriguez S, Guo WH, Giraud J, and Lopez MF. IRS-2 Plays an Important Role 
in the Signaling of Igf-2 in Fetal Hepatocytes. 2006. Fifth Annual New England 
Science Symposium (sponsored by the Harvard Medical School and the 
Biomedical Science Careers Program), Boston, MA (poster presentation). 
 
Rodriguez S, Guo WH, Giraud J, Lopez MF. 2005. Igf2 Regulates Insulin 
Receptor Substrate 2 Expression in the Fetal Liver. Program of the 87th Annual 
Meeting of the Endocrine Society, San Diego, CA (oral presentation). 
 
Rodriguez S, Vera Y, V Pope, M Castanares, YH Lue, V Atienza, C Wang, RS 
Swerdloff and AP Sinha Hikim. 2004. Functional Role of Caspases in Heat- 
Induced Testicular Germ Cell Apoptosis. Western Student Medical Research 
Forum, Carmel, CA (oral presentation and Western Student Medical Research 
Forum Endocrinology Subspecialty Award). 
 
Rodriguez S, Vera Y, Diaz-Romero M, Lue YH, Atienza V, Wang C, Swerdloff 
RS, Sinha Hikim AP. 2003. Protection of Heat-Induced Testicular Germ Cell 
Apoptosis in Mice by a New Generation Broad-Spectrum Caspase Inhibitor. 
Program of the 85th Annual Meeting of the Endocrine Society, Philadelphia, PA 
(oral presentation). 
 
Rodriguez S, Vera Y, Lue YH, Diaz-Romero M, Wang C, Swerdloff RS, Sinha 
Hikim AP. 2003. Translocated Cytosolic DIABLO Through Interaction with XIAP 
 105 
Regulates Heat-Induced Testicular Germ Cell Apoptosis in FAS Ligand-Defective 
Mice. Western Section AFMR, Carmel, CA (oral presentation). 
 
Rodriguez S, Lue YH, Diaz-Romero M, Yen PH, Wang C, Swerdloff RS, Sinha 
Hikim AP. 2002. Involvement of Diablo in Heat-Induced Testicular Germ Cell 
Apoptosis in FAS Ligand-Defective Mice. Program of the 84th Annual Meeting of 
the Endocrine Society, San Francisco, California (oral presentation; recipient of a 
travel grant award). 
 
Hikim AP, Lue YH, Rodriguez S, Yen PH, Wang C, Swerdloff RS. Activation of 
the Mitochondria-Dependent Apoptotic Pathway in Heat-Induced Germ Cell 
Apoptosis in FAS Ligand-Defective Mice. 2002 Program of the 27th Annual 
Meeting of the American Society of Andrology, Seattle, Washington (oral 
presentation). 
 
Rodriguez S, Lue YH, Yen PH, Swerdloff RS, and Sinha Hikim AP. 2002. 
Activation of the Mitochondria-Dependent Apoptotic Pathway in Heat-Induced 
Testicular Germ Cell Apoptosis in Mice.Western Student Medical Research 
Forum, Carmel, Ca (oral presentation). 
 
Reviews: 
Rodriguez S and Wolfgang MJ. Regulation by Fatty Acids/Malonyl-CoA in the 
Brain. Encyclopedia of Biological Chemistry 2nd Edition, Elsevier Inc., In Press. 
2013 
 
Manuscripts in Preparation: 
Rodriguez S, Ellis J, Wolfgang MJ. 2014. In vivo Chemical-Genetic of Skeletal Muscle 
Malonyl-CoA Decarboxylase Does Not Improve Insulin Sensitivity. BMC Biochemistry. 
 
Rodriguez S, Ellis J, Wolfgang MJ. 2014. In vivo fatty acid oxidation of 
radiolabeled substrates. JOVE. 
 
 
 
 
 
 
 
 
 
 
 
 
 
